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Abstract 
 
 The ethical foundation of clinical research is informed consent. Biobanking has added to 
the complexity of the informed consent process. Biomedical research with human biospecimens 
often occurs without any consent or with inadequately understood consent information. Yet, the 
use of biospecimens in research is not without controversy. 
 One abundant source of biospecimens for research is residual dried blood spots (rDBS) 
from newborn screenings. Approximately 4 million infants are born annually in the United States 
(U.S.) and most have mandatory newborn screening. In 2010, the state of Michigan implemented 
a process of written parental consent for donating newborns’ residual dried blood spots to the 
Michigan BioTrust for research. Thus, biobanking of newborn rDBS in Michigan presented a 
prime opportunity to study mothers’ level of knowledge, attitudes, values, and decision-making 
after a broad consent process for donating their newborn’s rDBS for research.   
 Therefore, the  purposes of this dissertation research are to  a) describe the current state 
of the science regarding participants’ understanding of informed consent for biobanking; b) 
describe the influence of mothers’ knowledge (understanding of biobanking), values (personal 
and religious), and perceptions of the informed consent process (content and context) on their 
decisions to donate their newborn’s rDBS for research purposes;  c) compare and contrast 
mothers’ knowledge of and attitudes towards biobanking, socio-demographics, and personal and 
religious values with their decisions (yes or no) to donate their newborn’s rDBs for research 
purposes and determine the proportion of informed choices.  
 xi 
A qualitative descriptive design, a non-experimental survey, and methodological 
triangulation are used in this three-paper style dissertation.  The first of the three papers (Chapter 
2) is a systematic review to evaluate participants’ level of understanding of the information 
presented during the consent process for donation of biological specimens for research purposes 
(i.e., for biobanking or genetic epidemiological studies).  Results indicated many elements of 
informed consent unique to biobanking were inadequately understood by potential participants.  
Next, semi-structured interviews (Chapter 3) were used to describe mothers’ understanding of 
biobanking, attitudes about rDBS research, and the influence of personal values on the decision-
making process. Findings indicated that while most mothers agreed (14/20; 70%) to donate the 
rDBS and expressed favorable attitudes about research, most decisions (16/20; 80%) were 
determined to be uniformed choices due to inadequate knowledge of the Michigan BioTrust and 
biobanking. A non-experimental, descriptive and correlational survey was randomly distributed 
to 500 mothers in the state of Michigan with a newborn age 0-3 months (Chapter 4) to examine 
knowledge, attitudes and values, and the proportion of informed choices in a larger sample using 
standardized instruments.  Just over half of the mothers (55%) in this study were deemed to have 
made an informed choice; however, knowledge scores were still low. On average, respondents 
were only able to correctly answer approximately 8/16 biobanking questions.  
With 4 million American newborns having blood spots each year there are significant 
policy implications to this research (Chapter 5). Three recommendations are put forth: include 
the ethical implications of biobanking in educational materials, enhance consenters’ knowledge  
about rDBS research and their communication skills for conducting informed consent processes, 
and move the educational content  about rDBS research to the prenatal setting (Chapter 5).  
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Chapter 1 Introduction 
 
Informed consent is a central tenet of the bioethical principles governing both medical 
treatment and clinical research. There are similarities in informed consent for medical treatment 
(e.g. surgery) and research including the obligation of the provider or researcher to disclose to 
the patient or potential participant the risks, benefits, nature of the procedure and alternatives 
(Levine, 1983; Beauchamp, 2011). However, while standard medical treatment is believed to be 
in the patient’s best interest, research may involve risks without any intended or direct benefit to 
the participant. Thus, informed consent in clinical research often involves more information and 
formality, and is highly regulated by the government (Levine, 1983; Beauchamp, 2011).  In 
clinical research, informed consent is an ongoing, interactive process in which an individual is 
given important information about voluntary participation in the research project (e.g. risks, 
benefits, and the right to withdraw at any time) before deciding whether or not to participate 
(National Cancer Institute [NCI], 2018).  For informed consent to be considered valid, adequate 
information must be provided by researchers. In addition, efforts must be made to ensure the 
potential participants understand the information provided (Faden & Beauchamp, 1986).  
However, as clinical research is becoming increasingly complex many individuals do not 
understand the informed consent information (Cohn & Larson, 2007; Falagas et al., 2009; Flory 
& Emanuel, 2004; Nishimura et al., 2013).   
This dissertation focuses on the concept of informed consent for clinical research, 
specifically, biobanking research. Biobanking, defined as the collection, storage, and 
management of human biological specimens (e.g. tissue, cells, blood) and/or associated personal 
2 
 
health information for future and often unspecified research activities (Biobanking and 
Biomolecular Resources Research Infrastructure [BBMRI], 2012; Henderson et al., 2013) has 
further added to the complexity of the informed consent process (Brothers, 2013; Rothstein, 
2005).  Since the completion of the Human Genome Project, millions of biospecimens have been 
preserved in private and public biobanking repositories (Collins, Green, Guttmacher, & Guyer, 
2003; Henderson et al., 2013). Biobanks vary greatly in their administrative governance (e.g. 
public, non-profit, academic, private, or for profit companies) and purpose (e.g. to conduct 
disease-focused research, and/or to facilitate research for other scientists by providing 
biospecimens; Henderson et al., 2013).   
Biospecimens are useful in research for at least two reasons.  First, they contain 
deoxyribonucleic acid (DNA), the molecule that constitutes genes and chromosomes and 
contains the unique genetic code of each individual.  DNA determines the expression of human 
physical traits, (e.g. eye color) and susceptibility to certain diseases (e.g. Alzheimer’s disease).  
Genomic sequencing provides information about an individual’s complete set of genes and 
important insights about individual and population health and human disease (Collins et al., 
2003; Rédei, 2008; International Human Genome Sequencing Consortium, 2004; NHGRI, 2010; 
Seemungal & Carr, 2001).  
  The second reason biospecimens are useful in research is because they are considered 
“naturally occurring raw materials” (Moore v. Regents of the University of California, 1990, 793 
P.2d at pp. 492-93; Rao, 2000) for use in the creation of genetically-engineered animals, cell 
lines, and embryos, increasingly used for scientific experimentation (Jones & MacKellar, 2009; 
Moore v. Regents of the University of California, 1990; Salvi, 2001).  Biobanks frequently 
supply scientists with biospecimens including specific human cells (e.g. fibroblasts, leukocytes) 
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and DNA for incorporation into these genetically-modified creations.  While the wealth of 
knowledge gleaned from this research has led to medical advances, the use of biospecimens in 
research is not without controversy.  
Statement of the Problem 
Biobanking has become an important part of scientific research and millions of 
biospecimens are collected for research each year. If, however, relevant consent information is 
omitted, inadequately provided, or inadequately understood, then individuals may make 
uninformed biobanking decisions (Eisenhauer, Tait, Rieh, & Arslanian-Engoren, 2017; Lewis, 
Goldenberg, Anderson, Rothwell, & Botkin, 2011; Wertz, 1999). The era of genetics and 
genomics has ushered in new types of biomedical research, bringing forth concerns about genetic 
privacy and the ethical use of human biospecimens (Brothers, 2013; Rothstein, 2005, 2010). 
Increasingly, empirical research describes the importance of personal, religious, and moral 
values regarding the use of biospecimens (Eisenhauer & Arslanian-Engoren, 2016; Modell, 
Citrin, King, & Kardia, 2014; Tomlinson, Kaplowitz, & Faulkner, 2014; Tomlinson, De Vries, 
Ryan, Kim, Lehpamer, & Kim, 2015).  Whether, and how, individuals incorporate their personal, 
religious, and moral values when making decisions about biobanking participation is an 
understudied, but important area of research that warrants further investigation, as uninformed 
choices may lead to decisional regret and moral distress.  
Significance of the Research 
While an abundance of evidence exists describing attitudes toward biobanking and 
preferences for type of consent (e.g. opt-in, opt-out, specific, tiered, or broad; Botkin et al., 2012; 
Brothers, Morrison, & Clayton, 2011; Hull et al.,2008; Igbe & Adebamowo, 2012; Murphy et al., 
2009; Simon, et al. 2011; Tarini et al., 2009; Thiel et al., 2014; Wong et al., 2004), there is a 
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paucity of empirical evidence that has evaluated whether decisions that result from the informed 
consent process for biobanking meet the standard of  informed decisions. Informed decision-
making requires adequate knowledge and consistency with one’s values (Marteau et al., 2001; 
O'Connor, Llewellyn-Thomas, & Flood, 2004).  Inadequate information, knowledge, and 
understanding may lead to biobanking participation decisions that are inconsistent with personal 
values, beliefs, and preferences (Tomlinson et al., 2014; Tomlinson, et al., 2015) and may result 
in dissatisfaction, decisional regret, moral distress, and a lack of trust and participation in future 
research (Modell et al., 2014; Rothstein, 2005; Tomlinson et al., 2014).  
This also has implications for personalized medicine, as it depends on a large, diverse 
quantity of biobanked specimens to establish generalizability of results. Finding the right balance 
and best method for biobanking consent requires empirical results describing how individuals 
make actual biobanking decisions, in their natural settings, and in real-time.  It also requires 
examining the role of personal and religious values and the diversity of beliefs.  Two recent 
literature reviews revealed few studies have addressed the influence of personal and religious 
values at the point of actual biobank specimen donation decisions (Eisenhauer et al., 2017; 
Eisenhauer & Arslanian-Engoren, 2016).   
Informed consent for genetics, genomics, and biobanking requires frank, open 
discussions with potential participants that include their values and explicit examples of various 
types of research for which biospecimens may be used (e.g. animal research, behavioral genetic 
research, creation of immortalized cell lines, embryonic stem cell research, germ-line gene 
therapy (GLGT), in vitro fertilization, preimplantation genetic diagnosis, prenatal genetic 
screening, and somatic nuclear cell transfer).  Providing accurate and balanced information is 
necessary, so participants can develop an informed understanding of biobanking research to  
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make decisions in alignment with their values.  By doing so, the informed consent process may 
be transformed from a perfunctory, rote process to one that provides meaningful information to 
participants, from which they can then consider whether or not to participate in the proposed 
research guided by their understanding (e.g. of risks and benefits) and their personal values.   
In addition to a lack of research on concerns about moral risk, studies that seek to 
determine participants’ understanding of informed consent information also often lack the use of 
standardized measures (Cohn & Larson, 2007; Falagas et al., 2009; Flory & Emanuel, 2004; 
Nishimura et al., 2013).   This dissertation begins to address these gaps by examining the 
influence of personal and religious values in biobanking decision-making, using standardized 
measures of knowledge, attitudes, informed choice, and biobanking consent information, during 
actual decision-making, in real-time and natural settings.  Analysis resulting from this work will 
provide the foundation for tailored interventions to facilitate informed choices in biobanking, and 
continued development of an emerging middle-range nursing theory of informed consent for 
clinical research (Eisenhauer & Arslanian-Engoren, 2016). 
Background 
Biobanking and Informed Consent 
Currently, in the United States (U.S.) a national policy debate is occurring regarding the 
consent requirements for the use of human biospecimens (Federal Policy for the Protection of 
Human Subjects, 2015; 2017; 2018).  Differing views among stakeholders include some 
believing that asking for consent will hinder the pace of biomedical research (Forsberg, Hansson, 
& Eriksson, 2011), while others believe it is an ethical requirement (Greely, 1999; Hofmann, 
2009; Rothstein, 2005).  Residual, non-identified biospecimens from clinical care (e.g. 
venipuncture, surgery), previous research studies, or currently existing in biobanks can be used 
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for research without informed consent. However, the use of identifiable biospecimens or 
biospecimens obtained specifically for research purposes requires written informed consent 
(United States [U.S.] Department of Health & Human Services [DHHS]. Office for Human 
Research Protections [OHRP], 2008).  Survey research shows most individuals support the goals 
of biomedical research, while at the same time many individuals want control over the use of 
their biological specimens and want to be asked permission for their research use (Botkin et al., 
2012; Brothers, Morrison, & Clayton, 2011; Hull et al.,2008; Igbe & Adebamowo, 2012; 
Murphy et al., 2009; Simon, et al. 2011; Tarini et al., 2009; Thiel et al., 2014; Wong et al., 2004).  
As a result, some agencies are now asking for consent to use biospecimens in research, even 
when it may not be required (Langbo, Bach, Kleyn, & Downes, 2013; Tarini & Lantos, 2013).  
Biobanking informed consent documents vary widely on the amount and type of 
information provided to potential participants (Master, Nelson, Murdoch, & Caulfield, 2012). 
Three common types of biobanking consent documents are study-specific, categorical (or tiered), 
and broad consent forms. Study-specific consent forms clearly describe the details of a single, 
specified study and allow the use of the participant’s biospecimen for a specified purpose and 
time frame. A categorical consent document allows a participant to grant permission for specific 
categories of research activities. Broad consent forms allow researchers to use participants’ 
biospecimens often for indefinite periods of time and for unspecified research purposes (Master 
et al., 2012).  Broad consent forms are often favored by researchers for their latitude, and are also 
frequently acceptable to participants as they provide some degree of choice and control (Grady et 
al., 2015).  However broad consent forms often lack specific details and may not be adequately 
understood by participants, raising ethical issues about its acceptability (Hofman, 2009). Despite 
these concerns, the use of broad consent for the use of identified biospecimens in research was 
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recently approved by the U.S. federal government (Federal Policy for the Protection of Human 
Subjects, 2017).  
Genetic Privacy  
Genetic privacy is a risk of biobanking participation.  Some ethicists argue this is more 
than minimal risk, especially when it involves proxy consent for minors because minors have a 
right to their own values that may not align with the values of the surrogate (Baumann, 2001; 
Caulfield & Weijer, 2009; Hens, Cassiman, Nys, & Dierickx, 2011; Hofmann, 2009).  Donated 
biospecimens provide researchers access to individuals’ genetic fingerprint.  Sequencing DNA 
reveals the donor’s genetic susceptibility to disease and potentially even adverse behavioral traits 
(Andrews, 2005; Rothstein, 2005). Analyzing the DNA of one family member can provide 
information about and create risks for other family members or an entire race, ethnicity, or 
religious group (Andrews, 2005; Rothstein, 2005), as it is now possible to definitively identify an 
individual using relatively little genetic material (Lin et al., 2004).  Further, biospecimens in 
biobanks are often linked to medical data or information in public health registries, creating 
additional privacy and discrimination concerns (Andrews, 2005).  Other concerns include linking 
specific genetic traits, especially those that hold social stigma (e.g. alcoholism, mental illness, 
criminality) to specific racial populations or religious groups, that may contribute to pervasive 
discrimination (Andrews, 2005; Rothstein, 2005; Wertz, 1999).   
Moral Risks 
Additional risks include moral risks:  the possibility that biospecimens and the knowledge 
they generate may be used in research activities or procedures that are misaligned with the 
donor’s (or surrogate’s) personal, religious, or cultural values (Modell et al., 2014; Rothstein, 
2005; Tomlinson et al., 2014; 2015).  Compared to privacy concerns, the threat to individuals’ 
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moral values is less understood as it relates to personal values, expectations, and human rights 
regarding stewardship or jurisdiction over one’s body and the right to bodily integrity in life and 
even after death (Young, 2012).  
Concerns include: religious prohibitions against blood storage, cloning, predicting the 
future, and trying to “play God” by analyzing and /or manipulating genetics (Eisenhauer & 
Arslanian-Engoren, 2016). Because future research use of biospecimens is often unspecified, 
alignment with personal values may not always be clear and should be explored during the 
informed consent process. Therefore, it is necessary to know if individuals considering biobank 
donation are given balanced information, presented with examples of various types of 
experiments conducted with biospecimens, and to determine how (or whether) individuals’ 
incorporate their values into the reasoning and decision-making processes. This requires eliciting 
and clarifying participants’ values during a consent process, and encouraging them to weigh the 
risks and benefits in light of their values.  
Newborns’ Blood Spots 
One abundant source of biospecimens for research is residual dried blood spots (rDBS) 
from newborn screenings. Approximately 4 million infants are born annually in the U.S and most 
have mandatory newborn screening tests (American Academy of Pediatrics, 2000; Hamilton et 
al., 2015).  Newborn screening programs, under the administration of state health departments, 
that choose to retain, store, and distribute rDBS for research purposes have become blood spot 
biobanks (Tarini & Lantos, 2013), with 20 states retaining rDBS for over one year (Olney, 
Moore, Ojodu, Lindegren, & Hannon, 2006). Laws and policies about the storage, retention, and 
parental consent for research use of rDBS vary widely across states (Lewis et al., 2011). 
Biobanks created without parental consent in Minnesota and Texas have resulted in lawsuits 
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(Bearder et al. v State of Minnesota et al., 2010; Beleno et al v. Texas Department of State 
Health Services et al. 2009).  In Texas, rDBS were sent to the military to create a forensic 
database and traded for laboratory equipment; state officials attempted to cover-up these 
activities (Ramshaw, 2010).  Eventually, Texas was required to destroy more than 5 million 
blood spot cards and parental concerns resulted in changes to state policies in both Texas and 
Minnesota (Carmichael, 2011).   
Michigan 
In 2009, Michigan Department of Health and Human Services (MDHHS) proactively 
created the Michigan BioTrust for Health (i.e. the “BioTrust”) to operationalize policies 
regarding the storage and research use of the newborn rDBS (Langbo et al., 2013). The BioTrust 
has three advisory boards to help inform policy development: a Community Values Advisory 
Board (CVAB), the Scientific Advisory Board (SAB), and the physical repository for the 
residual dried blood spots, the Michigan Neonatal Biobank (MNB) has its own board of directors 
(Langbo et al.). In 2010 MDHHS implemented a process of written parental consent (broad 
consent) for donating newborns’ residual dried blood spots to the BioTrust for research (Langbo 
et al.).  Thus, biobanking of newborn rDBS in Michigan presented a prime opportunity to study 
mothers’ level of knowledge, attitudes and values, decision-making and the proportion of 
informed choices, after a broad consent process for donating their newborn’s rDBS for research.  
While it is laudable to ask for consent, even broad consent, it is also important to determine if the 
information is understood and being used to make an informed choice: a choice consistent with 
adequate knowledge and the decision maker’s values (Marteau, et al., 2001).    
Specific Aims 
 The aims of this dissertation research are to: 
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1) Describe the current state of the science regarding participants’ understanding of 
informed consent for biobanking. 
2) Describe the influence of mothers’ knowledge (understanding of biobanking), values 
(personal and religious), and perceptions of the informed consent process (content and context) 
on their decisions to donate their newborn’s rDBS for research purposes.    
3) Compare and contrast mothers’ knowledge of and attitudes towards biobanking, socio-
demographics, and personal and religious values with their decisions (yes or no) to donate their 
newborn’s rDBs for research purposes and to determine the proportion of these decisions that are 
deemed informed.  
Theoretical Framework  
 The theoretical framework for this study was The Marteau et al. (2001) Multidimensional 
Measure of Informed Choice (hereafter: MMIC; Figure 1). The main concepts are knowledge, 
attitudes, and the participation decision. Knowledge is defined as participants’ understanding of 
key information about a topic, including risks, deemed essential by professional consensus for 
making an informed choice.
 
 Attitudes are value-judgements about facts and information.  In this 
model, each concept has two possible dichotomous outcomes; knowledge may be good or poor; 
attitudes may be positive or negative, and the participation decision may be yes or no.  
According to the Marteau et al. (2001, p. 100) informed choice is defined as “one that is based 
on relevant knowledge, consistent with the decision-maker's values and behaviourally 
implemented”. Using this definition, only two different combinations of knowledge, attitudes 
and participation decisions are considered informed choices (Figure 1). Thus, if the participation 
decision is both based on a good level of knowledge and consistent with attitudes and values, the 
decision is classified as an informed choice. However, if the participation decision is based on a 
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poor level of knowledge and/or inconsistent with the participant’s values the decision is 
classified as an uninformed choice.  All other outcomes are uninformed choices (Figure 1). 
While the MMIC has been used to study prenatal testing decisions (Marteau et al. 2001; Piechan 
et al. 2016; van den Berg, Timmermans, ten Kate, van Vugt, & van der Wal, 2006), to the best of 
knowledge, this is the first study that uses it to frame choices about biobanking research.  
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Figure 1. Informed Choices per Marteau et al. 2001 
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Figure 2 depicts the Marteau et al. (2001) model of informed choice in the context of an 
informed consent process. The Information-Motivation and Behavioral Skills Model (IMB) 
(Fisher & Fisher, 2000) and the Process and Quality of Informed Consent (P-QIC) tool designed 
by Cohn, Jia, Smith, Erwin, & Larson (2011) also influenced the development of this synthesized 
model.  Information is transmitted through a communication process that requires specialized 
training and skills and feedback should be elicited from the participant to ensure understanding 
(Cohn et al., 2011). The quality of this process is dependent in part on the educational level and 
training of the consenter, who is also influenced by his/her own knowledge and attitudes and 
needs to know how to manage them in the context of a consent relationship.  Moreover, the 
potential participant’s knowledge and attitudes are related and informed by each other (Fisher & 
Fisher, 2000). Individuals apply value judgements to factual information and contextual 
situations, and values are often combinations of knowledge and beliefs (Fisher & Fisher, 2000; 
Rokeach, 1979).   
Research Design 
 This dissertation used a non-experimental, descriptive design with methodological 
triangulation. Triangulation is a study design that includes qualitative and quantitative methods 
that complement each other to provide a more comprehensive understanding of the construct’s 
dimensions compared to one method alone (Polit & Hungler, 1999).  Each component had 
distinct sampling, data collection, analysis, and results; findings were subsequently combined in 
an overall discussion and interpretation of the study.  Further, this dissertation followed a three 
paper manuscript-style format.  The first chapter is the introduction, followed by three papers 
that present a comprehensive and cohesive report on a completed research project, and a 
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discussion chapter synthesizing the three papers and presenting directions for future research 
(School of Nursing, University of Michigan, 2015).  
Figure 2. Synthesized Model of Informed Consent for Biobanking with Informed Choices 
 
One advantage of this dissertation format is rapid dissemination of results for publication, which 
is consistent with the intention that the results of this dissertation research to improve and protect 
informed consent.  
The first of the three papers (Chapter 2) is a manuscript entitled, Participants’ 
Understanding of Informed Consent for Biobanking: A Systematic Review. It was completed as 
part of preliminary study work, co-authored, and is currently an online publication in Clinical 
Nursing Research (Eisenhauer et al., 2017).  The purpose of the systematic review was to 
evaluate participants’ level of understanding of the information presented during the consent 
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process for donation of biological specimens for research purposes (i.e., for biobanking or 
genetic epidemiological studies). It included 34 studies: nine qualitative; 21 quantitative; and 
four mixed-method studies. Results indicated that many elements of informed consent unique to 
biobanking (e.g. risks of biobanking, access to specimens, the role of genetics, and the return of 
genetic results) were inadequately understood by potential participants.  A possible source of 
bias was uncovered in that 30 studies (88%) had an author associated with a biobank or biobank-
related funding.   In addition, there was substantial variation in the elements of informed consent 
assessed for understanding and the measurement of understanding across the studies.  Only one 
study explicitly disclosed and assessed understanding of the moral risks associated with 
biospecimen donation (and understanding was inadequate).  A number of contextual factors were 
found to influence understanding and included (a) circumstances of recruitment (e.g. member of 
the public approaches researcher; researcher approaches a patient); (b) education, literacy, and 
reading; (c) consent modalities (e.g. paper/reading, computer module, human/verbal interaction); 
(d) locality; (e) other demographics (e.g., age, gender, and income) (f) consenters (e.g. nurses, 
physicians); and (g) amount of time spent explaining consent information.  Recommendations 
based on the review included incorporating updated health literacy recommendations that do not 
rely solely on patient education, but also emphasize improving healthcare provider 
communication skills and re-designing institutional processes to facilitate informed choices.  
The focus of the qualitative component of this dissertation research was to describe 
mothers’ understanding of biobanking, attitudes about rDBS research, and the influence of 
personal values on the decision-making process. This was accomplished in two ways: 1) by 
conducting passive participant observation of the consent process and 2) by conducting semi-
structured interviews with postpartum mothers, immediately after they decided whether or not to 
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donate their newborn’s rDBS for research. Findings indicated that while most mothers agreed 
(14/20; 70%) to donate the rDBS and expressed favorable attitudes about research, most 
decisions (16/20; 80%) were determined to be uniformed choices due to inadequate knowledge 
of the Michigan BioTrust and biobanking. The study is presented in Chapter 3.   
The focus of the quantitative component of this dissertation research was to examine 
knowledge, attitudes and values, and the proportion of informed biobanking choices in a larger 
sample using standardized instruments.  A non-experimental, descriptive and correlational 
survey was randomly distributed to 500 mothers in the state of Michigan with a newborn age 0-3 
months.  Standardized measures were used to measure key variables including biobanking 
knowledge and attitudes, intrinsic religiosity and other personal values (Wells et al., 2014; Hoge, 
1972; Lindeman & Verkasalo, 2005), an element often lacking in other studies on participants’ 
understanding of informed consent (Cohn & Larson, 2007; Eisenhauer et al., 2017; Falagas et al., 
2009; Flory & Emanuel, 2004; Nishimura et al., 2013).  While the number of respondents was 
small (N=80), the study generated insightful empirical data on the proportion of mothers’ 
informed choices about the BioTrust. Findings from this study indicate that knowledge and 
experience contribute to making an informed choice about biobanking. Results are presented in 
Chapter 4.  
The results of both components are examined, compared, and contrasted with existing 
literature, and implications for policy recommendations and future work are discussed in Chapter 
5.   
Implications for Nursing 
Nurses play an integral role in care and patient education along the entire continuum of 
maternal–child care from early pre-natal care to delivery and beyond.  As such, nurses should 
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have knowledge of the fundamental values of the nursing discipline: altruism, autonomy, human 
dignity, integrity, and social justice and professionalism. Because of this special preparation they 
are in a position to assume roles in which they conduct the consent process.  Nurses play a 
central role in clinical research, often employed as clinical research coordinators (Hastings, 
Fisher, McCabe, & National Clinical Research Nursing Consortium, 2012).  Thus, nurses need to 
be aware of the potential issues that patients and other biobanking participants may consider 
and/or that influence the decision-making process (Eisenhauer et al., 2017).  Indeed, the 
American Nurses Association (ANA) recently endorsed clinical research nursing as a specialty 
nursing practice (Zaparoni, 2016).   
This phenomenon has further implications for nursing.  Definitions of evidence based 
nursing (DiCenso, Guyatt, & Ciliska, 2005), patient–centered care (Berwick, 2009), and shared 
decision-making (Elwyn et al., 2012) promote the inclusion of patients’ values in decision-
making. As healthcare professionals, nurses are expected to advocate for the value-based 
decisions of their patients.  Baccalaureate nursing graduates are taught to practice from a holistic, 
caring framework, and provide patient-centered care that identifies, respects, and advocates for 
patients’ values and preferences (AACN, 2008).   Care is a foundational concept for nursing and 
involves veracity, trust, and the skillful application of specific measures (Carper, 1979; Watson, 
1988/2007).   
 The use of the MMIC (Marteau et al. 2001) contributes to nursing practice by providing 
guidance on factors that influence patients' decision-making. This theory emphasizes knowledge, 
attitudes, and choice and highlights the importance of discussing these elements with patients. 
Nurses have not just a social mandate, but a covenant with the public (Fowler, 2017) and a 
responsibility to uphold and advocate for the true meaning of informed consent.  Moving beyond 
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autonomy alone, facilitating a truly informed choice demonstrates respects for the dignity, worth, 
values, and moral agency of each human being. 
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Abstract 
 Nurses are increasingly asked to obtain consent from participants for biobanking studies. 
Biobanking has added unique complexities to informed consent. The purpose of this systematic 
review was to evaluate participants’ level of understanding of the information presented during 
the informed consent process unique to the donation of biological specimens for research. 
PRISMA guidelines were utilized to conduct the review. PubMed, EMBASE, CINAHL, 
PsycINFO, Scopus, Web of Science, and ProQuest bibliographic databases were searched. 
Results indicated that elements of informed consent unique to biobanking were poorly 
understood. Most studies had authors or funding associated with a biobank. Only one study 
disclosed and assessed participants’ understanding of moral risks. Increased disclosures, values-
clarification, and presenting information via multiple modalities may facilitate understanding. 
There is a need to improve the quality of informed consent for biobanking studies by utilizing 
standardized instruments, definitions, and encouraging research about informed choice outside 
the biobanking industry. 
Keywords 
Biological specimen banks, Biobanking, Informed consent, Moral risks, Understanding 
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Introduction 
 Clinical research increasingly involves biobanking, the collection of human biological 
specimens (e.g. tissue, cells, blood, DNA) and related clinical data for future, often unspecified, 
research activities (Biobanking and Biomolecular Resources Research Infrastructure [BBMRI], 
2012; Henderson et al., 2013).  The mapping of the human genome and genetic-engineering have 
revolutionized the use of biospecimens.  However, this scientific progress has made 
understanding informed consent information more difficult.  In part, this difficulty is because 
biobanking research includes social and moral issues that distinguish it from participation in 
traditional clinical trials that do not involve a biobanking component (i.e. those without 
biospecimen collection) (Rothstein, 2005).  Nurses play a central role in clinical research, often 
employed as clinical research study coordinators (Hastings et al., 2012), and may be responsible 
for obtaining consent from participants for biobanking studies.  Thus, nurses may need to be 
aware of the unique difficulties patients may face during the decision-making process.  
Privacy and Dignitary Risks 
 Consent for biobanking differs from consent for participation in traditional clinical trials 
in several important ways.  First, genetic research, noted to be one of the most frequently 
conducted biobanking activities (Henderson et al., 2013), carries unique privacy risks to the 
participant and extended family members, as genetic analysis may reveal susceptibility to a host 
of diseases and potentially even personal behavioral traits (Rothstein, 2005).  Beyond genetic 
privacy, however, there is a relationship between biobanking and associated biotechnological 
procedures that may not align with some participants’ religious or personal values.  Such 
procedures may include: animal research, creation of immortalized cell lines, embryonic stem 
cell research, germ-line gene therapy (GLGT), in-vitro fertilization, pre-implantation genetic 
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diagnosis, prenatal genetic screening, and somatic nuclear cell transfer (i.e. research cloning) 
(Modell, Citrin, King, & Kardia, 2014; Rothstein, 2005, Tomlinson, Kaplowitz, & Faulkner, 
2014).  Ethicists have labelled the moral, religious, or cultural concerns of potential biobank 
participants as “dignitary risks” (Rothstein, 2005) or more recently as “non-welfare interests” 
(Tomlinson et al., 2014).  Indeed, potential biobank participants have expressed concerns about 
biobanking violating tenets of their religion. Concerns include religious prohibitions against 
blood storage, cloning, predicting the future, and trying to “play God” by analyzing and /or 
manipulating genetics (Eisenhauer & Arslanian-Engoren, 2016).  If individuals participating in 
biobanking research were to discover that they had inadvertently contributed to applications, 
procedures, or research to which they hold moral reservations, they may suffer decisional regret 
or moral distress, and may eventually distrust medical researchers (Modell, et al. 2014; 
Rothstein, 2005, Tomlinson et al., 2014).   
Information and Consent 
 Biobanking informed consent documents can vary widely on how much information 
about the research is given to potential participants.  There are three common types of 
biobanking consent documents in use today: study-specific (or classical or traditional), tiered (or 
menu or line item), and broad (or blanket) consent forms (ISBER, 2012; Master et al., 2012; 
Weir, 2000; Wertz, 1999).  Study-specific consent forms clearly describe the details of a single, 
specified study and allow the use of the participant’s biospecimen only for this specified purpose 
and time frame. A tiered informed consent document allows a participant to grant permission for 
some portion(s) of the research project, but not necessary all portions, as determined by the 
participant.  Choices may include the research purposes for which the biospecimen may be used, 
who has access to the biospecimen or associated data, and permission for use of the biospecimen 
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in future research projects.  Broad consent forms allow researchers substantial latitude in the use 
of participants’ biospecimens, often for indefinite periods of time and with few details of future 
use.  Broad consent forms may inadequately inform participants of their choices and the 
consequences of their decisions (ISBER, 2012; Master et al., 2012; Weir, 2000; Wertz, 1999).  
For example, specimens originally collected for diabetes research could later be used for 
researching alcoholism or addiction, ancestral origins, aggressiveness or criminality, mental 
illness, reproduction, and sexual orientation, and this may offend biospecimen donors’ values 
(Harmon, 2010; Weir, 2000; Wertz, 1999).   
 Presenting patients with different types, levels, and amounts of information may result in 
disparate understanding of biobanking research, and different decisions about participation 
(Abhyankar, Summers, Velikova, & Bekker, 2014; Tomlinson et al., 2014). Tomlinson et al. 
(2014) compared the biobanking donation decisions of individuals presented with either a brief 
or expanded description of a biobanking research project. For example, when the possibility of 
contributing to an increase in abortions was described in a biobanking project for creating a 
prenatal genetic test for cystic fibrosis, the number of pro-life participants willing to donate a 
biospecimen dropped from 87.5% to 61.7% (Tomlinson et al., 2014). This result indicates that 
when provided explicit information about the use of biospecimens, potential participants are able 
to assess the personal, moral implications of biobanking, which may enhance their understanding 
and affect their donation decisions. Thus, biobanking has unique characteristics that increase the 
complexity of the informed consent process, and the understanding thereof.   
 The purpose of this systematic review, therefore, was to evaluate participants’ level of 
understanding of the information presented during the informed consent process unique to the 
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donation of biological specimens for research purposes (i.e. for biobanking or genetic 
epidemiological studies).  Specific research questions were:  
 Research Question 1: What types of information are presented to prospective biobanking 
participants?  
 Research Question 2: What specific elements of informed consent are assessed for 
understanding?  
 Research Question 3: How is participants’ understanding of informed consent measured?  
 Research Question 4: What types of contextual factors influence understanding of informed 
consent for biobanking?  
Methods 
 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (i.e. The 
PRISMA Statement) was used as a guide to conduct this systematic review (Moher, Liberati, 
Tetzlaff, Altman, & The PRISMA Group, 2009).  In January 2015, a protocol for this review was 
registered on PROSPERO (registration number: PROSPERO 2015:CRD42015015649).  The 
protocol can be accessed from the following link: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015015649 
Systematic searches of the PubMed, EMBASE, CINAHL, PsycINFO, Scopus, Web of Science, 
and ProQuest databases were conducted during November, 2014-March, 2015. The searches 
were updated in November, 2016; three new, relevant studies were identified and incorporated 
into the results. 
Eligibility Criteria 
Studies included in this review were (1) written in English; and (2) included healthy or ill adults 
(≥18 years of age), volunteers or surrogates (for children or incapacitated adults), who 
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participated in an informed consent process for donating biospecimen(s) to an actual or 
hypothetical biobank for research purposes.  Further, included studies needed to contain a 
qualitative or quantitative assessment of participants’ understanding of the information presented 
during the informed consent process.  Studies were excluded that (1) only presented results about 
attitudes, preferences, willingness to donate to, or general knowledge of biobanking, without 
assessing understanding of informed consent, and/or (2) focused on the donation of 
biospecimens for clinical, diagnostic, or therapeutic purposes (i.e. non-research purposes) or 
biospecimens from fetal tissue or deceased donors. Conference abstracts, duplicate publications, 
editorials, essays, literature reviews, master’s theses, newspaper articles, opinion pieces, 
philosophical articles, posters, secondary analyses, and theoretical papers were also excluded.  
Search Strategy and Study Selection 
The search strategies included controlled vocabulary terms (i.e. Medical Subject Headings 
[MeSH®]), keywords, and synonyms for the concepts of informed consent, biobanking, and 
understanding/comprehension including: informed consent, consent forms, consent, biological 
specimen banks, genetic databases, biobank, comprehension, and understanding.  Searches were 
adapted as necessary based on the controlled vocabulary terms and functions of each database.  
Although theses and abstracts were excluded, relevant dissertations were mapped to published 
articles.  Reference lists of included studies were searched for additional relevant citations. Titles 
and/or abstracts of studies retrieved during the search phase were screened for inclusion by two 
authors (EE, CAE).  If relevancy could not be determined from the title or abstract, the full-text 
was skimmed.  Screened studies that addressed the inclusion criteria were retrieved and read in 
full.  Search and selection processes are presented in Figure 3.  
Data Extraction and Synthesis 
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A data extraction form was designed by (EE) and refined by (CAE) to capture 14 pertinent 
outcome and contextual variables from each included study (data available upon request).  A 
table (Table 1) was created delineating key elements of informed consent for biobanking 
(Beskow, Dombeck, Thompson, Watson-Ormond, & Weinfurt, 2015; Joffe, Cook, Cleary, Clark, 
& Weeks, 2001; Protection of Human Subjects, 2009).  Studies varied by the number of elements 
of informed consent measured for understanding (Table 2), thus data were further organized by 
the elements of informed consent and the level of understanding for that element as measured in 
each study (data available upon request).  We then categorized these measurements using a 
modified version of the method used by Falagas et al. (2009), using a threshold of ≥80% 
participant understanding to define adequate understanding.  Qualitative studies were 
synthesized separately from the quantitative studies.  Key words describing the level of 
understanding in qualitative studies were analyzed.  This was done to reflect understanding of 
informed consent using narrative descriptions and to compare the outcome of understanding 
between the quantitative and qualitative studies.   
Risk of Bias and Quality Assessment 
The Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool was 
used to evaluate the quality of included studies (Dearholt & Dang, 2012).  However, because this 
tool did not capture the critical elements of quality and bias in informed consent studies, we also 
used a modified checklist of additional items based on the work of Edwards, Lilford, Thornton 
and Hewison (1998) and Cohn and Larson (2007) (Appendix A).  The Cochrane Collaboration 
recommends assessing other sources of bias (Higgins et al., 2011); thus, we added an item that 
assessed the risk of bias in biobanking studies: author or funding source associated with a 
biobank, as discussed by Master et al. (2012) and Roessler, Steneck, and Connally (2015).  Study 
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quality and risk of bias was initially assessed by one author (EE) and 11 studies were randomly 
assessed for accuracy (using every third included study in alphabetical order) by a second author 
(CAE).  Quality rating disputes were reconciled by discussion until 100% consensus was reached 
on the final quality and bias assessments (Table 3).  
Results 
Study Characteristics  
A total of 34 studies were included in this review (Table 4): nine were qualitative (26%), 21 were 
quantitative (62%), and four used a mixed-method approach (12%).  Sample sizes ranged from   
as few as nine to as many as 2,192 participants.  Nine studies involved hypothetical decision-
making, while 25 involved actual decisions to biobank specimens (Table 4).  Additional 
variables describing the included studies are presented in Table 4.   
Risk of Bias and Quality Assessment 
Using the Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool 
(Dearholt & Dang, 2012) two studies (6%) received a low rating. However, 24 studies (71%) 
received a low (0-2 out of 6 possible points) rating using the tool specific to informed consent 
studies (Table 3).  Yet, the decision was made to include all of the studies in the review in order 
to better reflect the state of the science of participants’ understanding of informed consent for 
biobanking.  Most notably, 30 studies (88%) had an author associated with a biobank or biobank 
related funding (Table 3).  Four studies were related to a single biobank (Mahnke et al., 2014; 
McCarty et al., 2007, 2008, 2015).  Detailed results of the quality assessment are presented in 
Table 3.   
Information Presented 
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Per our inclusion criteria, all participants had undergone an informed consent process for 
biobanking.  Only one study explicitly disclosed and assessed understanding of moral risks 
associated with biobanking and reported inadequate understanding of these issues (McCaughey 
et al., 2016).  However, it is difficult to truly ascertain what specific or additional information 
was provided to participants as only 11 studies actually provided the biobanking informed 
consent document (whole or partially) (Table 3).  Thus, it is difficult to truly ascertain what 
specific or additional information was provided to participants.  This frequent lack of disclosure 
raises a concern about transparency in studies of participant understanding of informed consent 
information for biobanking.  
Understanding: Assessed and Reported  
Across the 25 studies reporting quantitative results, understanding of the selected elements of 
informed consent was most frequently measured at < 80% (Table 2).  Generally, participants 
understood their participation was voluntary and that they would not be paid for commercial 
products that could result from their donated biospecimens. Participants showed highly variable 
rates of understanding in their awareness of participating in a research project, benefits to self 
and others, who to contact with questions about the study, procedures, purposes, and that they 
could withdraw from a study. Understanding of the risks of biobanking and the experimental 
nature of research were particularly poor.  Inadequate understanding was especially prevalent in 
the following elements of informed consent: alternatives to participation, access to study 
records/specimens, collection data from personal medical records, confidentiality, injury 
compensation, the role of genetics including  DNA banking & storage, study duration, and  
return of genetic results (data available upon request).  Many poorly understood elements are 
unique to biobanking.  Participants’ self-rating of their understanding was usually higher than 
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understanding scored on objective measures (Klima et al., 2014; McCarty et al., 2007; 
McCaughey et al., 2016; Ormond et al., 2009). 
 Qualitative studies also frequently described participants’ understanding as inadequate.  Four 
of the nine (44%) qualitative studies clearly reported participants’ understanding as inadequate 
(Barr, 2006; Dixon-Woods et al. 2007; Ducournau et al., 2009; Hoeyer, 2003). Four other (44%) 
studies described participants’ understanding as riddled with “ambiguity” (Busby, 2004, p.46), 
“confused” (McCarty et al., 2008, p.3030; McGraw et al. 2012, p. 16), or “debatable” (Allen et 
al., 2011, p.159).  Beskow and Dean (2008) reported that participants “seemed to understand” (p. 
1447) the information provided. 
    Studies varied widely on the number of elements of informed consent assessed for 
understanding (Range 2-16) (Table 2).  Studies that used the Quality of Informed Consent 
(QuIC) instrument were most comprehensive in their assessments, assessing an average of 15 
elements of informed consent for biobanking (Klima et al., 2014; McCarty et al., 2007, 2015; 
Ormond et al., 2009; Simon et al., 2015). Originally designed for use in cancer clinical trials, the 
QuIC is a standardized instrument, with published reliability and validity data, that assesses both 
objective and subjective understanding about specific elements of informed consent using 20-
detailed true/false and 14-Likert scale questions (Joffe et al. 2001). The QuIC has been adapted 
and used in several studies (noted above) for assessment of understanding of informed consent in 
biobanking studies. 
Measurement of Understanding 
The methods and instruments used to assess understanding varied widely among studies.  
Methods included: in-person interviews (nine studies), telephone interviews (one study), verbally 
administered surveys (five studies), and self-administered surveys (16 studies), including some 
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that were mailed (six studies) or electronic (four studies) (Table 4).  Twenty-three of the 34 
studies (68%) included some validation of their instrument or interview guide, while 11 studies 
(32%) did not address validity (Table 3).  Only six studies used a previously validated instrument 
to assess understanding (Bickmore et al., 2009; Klima et al., 2014; McCarty et al., 2007, 2015; 
Ormond et al., 2009; Simon et al., 2015).  Five studies used the QuIC instrument (Klima et al., 
2014; McCarty et al., 2007, 2015; Ormond et al., 2009; Simon et al., 2015) and one used the 
Brief Informed Consent Evaluation Protocol (BICEP) (Bickmore et al., 2009).  One of the 
studies that used a self-administered survey also reported the initial reliability (Cronbach alpha 
of 0.73) and validity data (content validity) for a newly developed instrument to measure 
surrogate consent for genetic studies (Shelton et al., 2015).   
Contextual Factors 
Contextual factors found to influence understanding included: (1) circumstances of recruitment; 
(2) education, literacy, and reading; (3) consent modalities; (4) locality; (5) other demographics 
(e.g. age, gender, & income) (6) consenters; and (7) amount of time spent explaining consent 
information.   
Health status and the setting in which participants were recruited (e.g. patient versus non-
patient; healthcare versus community) varied across the studies, affecting the understanding of 
informed consent information.  Differences in understanding (Ormond et al., 2009; Toccaceli et 
al. 2009) or in the amount of time spent considering information (Roessler et al., 2015) were 
reported when participants were self-referred versus recruited in the healthcare setting. 
Understanding differed based on level of education in 9 studies (Beskow et al. 2017; Cervo et 
al., 2013; Joseph et al., 2008; Marshall et al., 2006; Merz & Sankar, 1998; Ormond et al., 2009; 
Panoyan et al., 2008; Petersen et al., 2014; Toccaceli et al. 2009).  Two studies identified better 
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literacy (or health literacy) as a factor associated with increased understanding (Bickmore et al., 
2009; Marshall et al., 2006).  The extent to which participants actually read study materials (i.e. 
all, part of, or none) was examined in two studies by Matsui et al. (2007, 2012).  Reading more 
of the informed consent document was associated with higher rates of self-perceived 
understanding.  However, no significant difference in reading amount was noted when given a 
shorter informed consent document (five pages) or a traditional longer document (11 pages) 
(Matsui et al., 2012) . Likewise, in a study by Beskow et al (2017), shorter documents did not 
improve understanding.  Education was not a statistically significant factor for increased 
understanding in the study by McCaughey et al. (2016), and despite the fact that 81.6% of their 
sample reported reading the information pamphlet at least once, understanding was still poor on 
objectives measures.  
Studies about computer-based informed consent often involved hypothetical biobanking 
decisions (Beskow et al., 2017; Bickmore et al., 2009; Mahnke et al., 2014; McGraw et al., 2012; 
Shelton et al., 2015).  While computer modules may occasionally lead to small gains in 
understanding, two authors cautioned that technology should be used as an adjunct to more 
traditional methods of informed consent including human interaction and reading of paper 
documents (McGraw et al., 2012; Shelton et al., 2015).  Interactivity, in the form of 
comprehension checks or quizzes, provided an important opportunity to review consent 
information, clarify confusion, and improve understanding (Beskow et al., 2017; Bickmore et al., 
2009; Simon et al., 2015).  Two computer studies involved actual biobanking decisions 
(McCarty et al., 2015; Simon et al., 2015):  McCarty et al. conducted a randomized controlled 
trial of traditional versus computer-based consent found no major differences in understanding. 
Simon et al. reported small gains in understanding in multimedia groups, but emphasized the 
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importance of interactivity across modalities.  Comparably, another study involving an actual 
biobank found repetition of consent information and presenting the information via multiple 
modalities (e.g. paper, media, humans) to be important factors in facilitating adequate 
understanding (Cervo et al., 2013).   
Locality, the cultural and sociopolitical environment of the participants, influenced their 
understanding of biobanking informed consent information (Hoeyer, 2003; Marshall et al., 2006; 
Petersen et al. 2014). For example, Hoeyer (2003) noted that in countries where the government 
finances health care, citizens may have a sense of wanting to give back to the government and 
therefore may be more likely to donate biospecimens to government-run research biobanks.  
Petersen et al. (2014) found perceptions of medical research and data protection standards varied 
in breast cancer patients from three European countries, and these varied perceptions influenced 
patients’ understanding of informed consent for biospecimen donation. 
Demographic (e.g. age, gender, income) composition of participants and reporting of these 
variables varied across studies.  Notably, younger age was usually (Beskow et al., 2017; 
Robinson et al., 2013; McCarty et al., 2007), but not always (Klima et al., 2014), associated with 
better understanding.  Females were more likely than males to demonstrate correct understanding 
(Klima et al., 2014; McCarty et al., 2007; Toccaceli et al. 2009),  as were individuals with or of 
higher levels of household income (Beskow et al., 2017; Joseph et al., 2008; Panoyan et al., 
2008).  Yet, Klima et al. (2014) found participants with higher levels of  household income were 
less likely to correctly answer the question of who would pay for a research related injury than 
those with incomes <$35,000.   
     Variability in the qualifications (e.g. physicians versus research assistants) and actions of the 
consenter may have influenced participants’ understanding of informed consent in ways that 
40 
 
have yet to be determined.  In eight studies (Beskow et al., 2017; Beskow & Dean, 2008; 
Mahnke et al., 2014; McCarty et al., 2008; McGraw et al., 2012; Merz & Sankar, 1998; Rahm et 
al., 2013; Shelton et al., 2015) participants only read a consent document and/or viewed a 
computerized version of the consent, with no human leading a consent discussion. Finally, 
estimated time to explain consent information varied across included studies, ranging from less 
than one minute to one hour.  
Discussion and Application 
 This systematic review indicates many elements of informed consent for biobanking are 
inadequately understood by participants.  These findings are consistent with research on 
understanding informed consent for traditional clinical trials and treatments (Cohn & Larson, 
2007; Falagas et al., 2009; Flory & Emanuel, 2004; Nishimura et al., 2013).   Our appraisal of 
the biobanking literature also revealed a unique finding of concern:  the vast majority (88%) of 
the included studies involving understanding of informed consent for biobanking had either an 
author associated with a biobank, genetic epidemiological study, or funding associated with these 
entities. While these associations are not evidence of wrongdoing, they may pose a risk of bias 
analogous to pharmaceutical funding of drug studies (Stelfox, Chua, O'Rourke, & Detsky, 1998) 
or the beverage industry sponsoring research on the health effects of soft drinks (Schillinger, 
Tran, Mangurian, & Kearns, 2016).   
 It was striking that only one study disclosed and assessed understanding of moral risks 
(McCaughey et al., 2016).  McCaughey et al. (2016) reported inadequate understanding of these 
moral risks to biobanking.  Most participants, however, could not consider this undisclosed 
information. This placed prospective biobank participants at a disadvantage, unable to evaluate 
all pertinent information when key aspects of moral controversy are omitted (Tomlinson et al., 
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2014).  A Notice of Proposed Rulemaking (NPRM) suggested strengthening human subject 
protection by requiring consent for the use of biospecimens in research (Federal Policy for the 
Protection of Human Subjects, 2015).  However, the final rule did not adopt the proposed 
requirement for consent involving non-identified biospecimens (Federal Policy for the Protection 
of Human Subjects, 2017).  As such, it remains to be seen whether there will be sufficient 
discussion of moral risks in the future to facilitate truly informed decisions (Marteau, Dormandy, 
& Michie, 2001).   
 Evidence from this review indicates the need for caution when recruiting in healthcare 
settings.  Contradictions were evident in participants’ understanding of the benefits of 
biobanking.  For example, even when they recognized that biobanking research was intended to 
help others, many participants still held expectations of benefits to themselves or their immediate 
loved ones (Barr, 2006; Busby, 2004;Dixon-Woods et al., 2007; Joseph et al., 2008;Klima et al., 
2014; McCarty et al., 2007, 2015; Ormond et al., 2009; Petersen et al., 2014).  These 
incongruencies may indicate therapeutic misconception, defined as when a research participant 
expects personal benefit, even when the goal of the study to benefit only future patients has been 
explained (Appelbaum, Roth, Lidz, Benson, & Winslade, 1987). 
    The emphasis on utilizing computers to deliver informed consent information may be a 
reflection of U.S. researchers’ increasing concerns about cost, time-savings, and efficiency 
(McCarty et al., 2015; Roessler et al., 2015).  However, this may also be indicative of an 
ethically detached approach to obtaining informed consent, typical in western countries (Carper, 
1979).  This approach may not be realistic when dealing with biobanking research involving 
value-laden, moral risks.  
Strengths and Limitations 
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 The strengths of this review include: (a) the use of the PRISMA guidelines (Moher et al., 
2009), including the online publication of a protocol; (b) exposing a risk of bias in research about 
participants’ understanding of biobank informed consent; and (c) revealing the lack of disclosure 
and assessment of understanding regarding moral risks in biobanking.  
Four limitations to this research are noted: (a) Included studies demonstrated vast 
heterogeneity in key characteristics: study designs, participant populations, interventions, and, 
especially, the definitions and measurements of understanding and the delivery of informed 
consent information.  Problems with such heterogeneity have been previously recognized in the 
literature as a limitation of studying understanding of informed consent (Cohn & Larson, 2007; 
Falagas et al., 2009; Flory & Emanuel, 2004; Nishimura et al., 2013; Sand, Kaasa, & Loge, 
2010).   The heterogeneity of measures in the included studies made accurate comparisons 
difficult.  (b) Moreover, the quality of included studies was lacking. There was frequent reliance 
on homogeneous convenience samples. Outcome measurements rarely involved the use of an 
instrument with published reliability and validity data.  Several studies were based on 
hypothetical decision-making, and many demonstrated a lack of transparency in reporting what 
information was disclosed to participants. There was immense variability and selectivity 
involving which elements of informed consent were assessed for understanding.  (c) In addition, 
only studies written in English were included, and (d) most studies were from the U.S. or 
Western Europe.  
Nursing Implications 
 This review demonstrates that participants’ biobanking decisions are not always truly 
informed; instead decisions may be based on limited understanding, values, trust, or even time 
constraints.  An uniformed participant may be at risk for decisional regret.  Nurses can help 
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guard against such potential errors in judgment by taking advantage of educational opportunities 
on genetics and genomic science, such as the Summer Genetics Institute (SGI) sponsored by the 
National Institute of Nursing Research (NINR) (NINR, 2017).  Nurses need to know, that 
without explicit explanations, patients may not understand the connections between donating 
biospecimens for research and controversial biotechnological procedures (Tomlinson et al., 
2014). To do so, nurses must first understand these distinctions in order to accurately convey this 
information to patients.  Next, nurses must be diligent not to exploit the strong trust of their 
patients (Hoeyer, 2003; Norman, 2016). Obtaining consent from patients for biobanking without 
providing adequate information and consideration for individual patient’s values is inconsistent 
with professional nursing values of respect for human dignity and the right to self-determination 
(American Nurses Association, 2015).  Assessing patients’ motivation for study participation and 
assessing their comprehension of biobanking and its implications are ways in which nurses can 
advocate for their patients (Penckofer, Byrn, Mumby, & Ferrans, 2011).  Further, to help patients 
make decisions more congruent with their personal values, and thereby avoid decisional regret, it 
may be helpful for nurses to describe some of the potential morally controversial uses of 
biospecimens (e.g. animal research, the creation of immortalized cell lines, and stem cell 
research) and include a disclaimer such as: “If any of these make you uncomfortable, you might 
not want to participate in this [biobank]” (University of Michigan, 2016).  
Recommendations for Practice and Future Research   
 Biobanking research involves presenting complex information to potential participants as 
they decide whether or not to grant their permission to participate in the research. Principles of 
health literacy apply to imparting such information. Health literacy is defined as “the degree to 
which individuals have the capacity to obtain, process, and understand basic health information 
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and services needed to make appropriate health decisions” (Ratzan & Parker, 2000, p.vi).  The 
field of health literacy has evolved from solely emphasizing patient education to focusing on 
provider communication skills, and more recently calling for an increase in transparent, patient-
friendly healthcare environments (Rudd, 2014).  For biobanking research, this three-fold 
approach to aid participants’ understanding of complex information includes: (a) increasing 
curriculum on genetics and biotechnology in secondary education, (b) emphasizing human-to-
human dialogue in the informed consent process, and (c) encouraging a more transparent 
research enterprise; one that encourages participants to make a truly informed choice (Marteau et 
al., 2001).  Recommendations for future research include improving the quality of studies on 
understanding informed consent for biobanking by utilizing standardized instruments, controlling 
for contextual variables, and establishing a common threshold for defining adequate 
understanding.  In addition, future work should include studies conducted by non-biobank 
associated researchers, with demographically diverse samples, and examine actual (not 
hypothetical) informed choices in real-time.  Future systematic reviews examining participant 
understanding of informed consent for biobanking should also examine these specific attributes.  
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Figure 3. Flow chart and study selection Moher et al., 2009. 
Note: This is Figure 1 in published article. 
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Table 1. Elements of informed consent for biobanking 
 
Access to Specimens or Data (Data Sharing) 
Alternatives 
Benefits 
Collect Data from Medical Record 
Confidentiality 
Contact Person 
Experimental  Procedures 
Injury 
No Penalty 
Payment/Commercial Use 
Purpose 
Research (Awareness of Participation) 
Re-contact 
Return of Results 
Risks 
Role/Knowledge of Genetics, Cells, DNA 
Study Duration 
Study Procedures 
Voluntary 
Withdrawal 
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Table 2. Understanding in included studies with quantitative results  
Exp=experimental group 
Included studies 
No. of key elements of informed consent for 
biobanking (Table 1) assessed for 
understanding 
Most elements 
<80% 
Yes/No 
1. Beskow et al., 2017 13 No 
2. Bickmore et al., 2009 Categories not provided---all mean scores <80% 
3. Cervo et al., 2013 2 No 
4. Joseph et al., 2008 7 No 
5. Klima et al., 2014 14 Yes 
6. Mahnke et al., 2014 7 No 
7. Mancini et al., 2011 3 Yes 
8. Marshall et al. 2006 2 Yes 
9. Marshall et al. 2014 6 No 
10. Matsui et al., 2012 3 No 
11. Matsui et al., 2007 N/A---Categories not provided 
12. McCarty et al., 2015 16 Yes 
13. McCarty et al., 2007 16 Yes 
14. McCaughey et al., 2016 6 Yes 
15. Merz & Sankar, 1998 6 Yes 
16. Moutel et al., 2001 3 Yes 
17. Ormond et al., 2009 15 Yes 
18. Panoyan et al., 2008 3 Yes 
19. Petersen et al., 2014 2 Yes 
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20. Rahm et al., 2013 5 Yes 
21. Robinson et al., 2013 2 Yes 
22. Roessler et al., 2015 89% self-rated their understanding at the highest level 
23. Shelton et al., 2015 9 
Control 
Yes 
Exp 
No 
24. Simon et al., 2015 16 No 
25. Toccaceli et al., 2009 3 Yes 
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Table 3. Quality Assessment of Included Studies 
Quality of Evidence and Risk of Bias    
Checklist for Studies of Informed Consent Item: Point(s)
a
 
Citation level/ 
grade
b
 
sampling  
hierarchy 
outcome  
measure 
response  
rate 
info 
supplied 
biobank 
affiliation 
Beskow et al., 2017 I/B 0 1 0 1 0 
Bickmore et al., 2009 I/B 0 2 0 1 1 
Matsui et al., 2012 I/B 1 0 1 1 0 
McCarty et al., 2015 I/B 1 2 1 0 0 
McGraw et al., 2012 I/B 0 1 0 0 0 
Robinson et al., 2013 I/B 1 1 1 0 0 
Shelton, et al., 2015  I/B 0 2 0 0 1 
Simon et al., 2015 I/B 1 2 0 0 0 
Matsui et al., 2007 II/C 1 0 1 0 0 
Allen et al., 2011 III/B 0 0 0 0 1 
Barr, 2006 III/B 0 0 0 0 0 
Beskow et al., 2008 III/B 0 1 0 1 0 
Busby, 2004 III/B 0 0 0 0 0 
Cervo et al., 2013 III/A 1 1 1 0 0 
Dixon-Woods et al., 2007 III/B 0 1 0 1 0 
Ducournau et al., 2009 III/C 1 0 0 0 0 
Hoeyer, 2003 III/B 0 0 1 0 0 
Joseph et al., 2008 III/B 0 1 0 0 0 
Klima et al., 2014 III/A 1 2 0 1 0 
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Mahnke et al., 2014 III/B 0 1 0 0 0 
Mancini et al., 2011 III/A 1 1 1 1 0 
Marshall et al., 2014 III/B 0 1 0 0 0 
Marshall et al., 2006 III/B 0 1 1 0 0 
McCarty et al., 2007 III/B 1 2 0 1 0 
McCarty et al., 2008 III/B 0 0 0 0 0 
McCaughey et al., 2016 III/A 0 1 0 1 0 
Merz & Sankar, 1998 III/B 0 1 0 1 0 
Moutel et al., 2001 III/B 0 0 0 0 1 
Ormond et al., 2009 III/A 0 2 0 0 0 
Panoyan et al., 2008 III/A 1 1 0 0 0 
Petersen et al., 2014 III/A 0 1 1 0 0 
Rahm et al., 2013 III/B 0 0 1 0 0 
Roessler et al., 2015 III/B 0 0 0 1 0 
Toccaceli et al., 2009 III/A 1 1 0 0 0 
a
See the Appendix A. Higher score indicates less risk of potential bias/higher quality.
b
Based on Dearholt and Dang 
(2012, Appendix E: Research Evidence Appraisal Tool, pp. 238-240). Quality rating based on quality appraisal: A = 
high quality; B = good quality; C = low quality; I = experimental study; II = quasi-experimental; III = descriptive or 
qualitative.   
  
51 
 
Table 4. Characteristics of Included Studies  
BICEP=Brief Informed Consent Evaluation Protocol instrument; QuIC= Quality of Informed Consent instrument 
Citation, Year, 
Country 
Design/Method Sample Information 
Allen et al., 2011, 
Australia 
Qualitative; semi-structured 
interviews 
Healthy cohort of participants (n=24) in 
actual biobank 
Barr, 2006, 
England 
Qualitative; semi-structured 
interviews 
Female patients (n=43) who donated  to 
actual biobank  
Beskow et al., 
2017, U.S. 
National online survey; 
randomized experiment 
Hypothetical decision-makers (n=1916) 
Beskow et al., 
2008, U.S. 
Qualitative; cognitive interviews Hypothetical decision-makers (n-40)   
Bickmore et al., 
2009, U.S. 
Randomized experiment using 
BICEP  
Hypothetical decision-makers (n=29)  
Busby, 2004, 
England 
Qualitative/ interviews  Donors (n=27)  to an actual genetic 
research project  
Cervo et al., 2013, 
Italy 
Descriptive; self- administered 
questionnaire 
Patients (n=430)  enrolled in actual 
biobank studies 
Dixon-Woods et 
al., 2007, England 
Qualitative; semi-structured 
interviews 
Healthy volunteers (n=29) in an  actual 
genetic study  
Ducournau et al., 
2009, France 
Qualitative; observation & 
interviews 
Men (n=60) offered a check-up & asked 
to participate in actual biobank  
Hoeyer, 2003,  
Sweden 
Qualitative; observation & 
interviews 
Donors and refusers (n=29) recruited  as 
participants in actual program offering 
check -ups 
Joseph et al., 2008, 
U.S. 
Survey; verbally administered, in-
person 
Female donors and refusers (n=93) to an 
actual biobank  
Klima et al., 2014, 
U.S. 
Survey; mailed, self- administered 
QuIC  
Parents (n=252) who actually enrolled 
their children to participate in 
congenital cardiovascular malformation 
research that included biobanking  
Mahnke et al., 
2014, U.S. 
Proof of concept study testing  
hypothetical computer-based 
consent  
Community members (n=9) 
representative of potential biobank 
participants  
Mancini et al., 
2011, France 
Mailed, self-administered, 12- page 
questionnaire 
Patients (n=574) treated for cancer and 
actually asked to donate tumor samples 
for research 
Marshall et al., 
2006, Nigeria & 
U.S. 
Qualitative & Quantitative; survey 
& interviews  
Clinic patients and controls (n=655) 
actually enrolled in genetic hypertension 
study in Nigeria & U.S. 
Marshall et al., 
2014, Nigeria 
Qualitative & Quantitative; survey 
& interviews 
Female cases and controls (n=215) 
enrolled in an actual genetic 
epidemiological study on breast cancer  
Matsui et al., 2012, 
Japan 
Intervention study; add-on cluster, 
randomized controlled trial  
Patients (n=336) actually consenting to 
genetic cohort study 
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Citation, Year, 
Country 
Design/Method Sample Information 
Matsui et al., 2007, 
Japan 
Descriptive study of intervention 
using a 2-question, in-person 
questionnaire  
Patients (n=2192) being asked to 
participate in actual genetic cohort study  
McCarty et al., 
2015, U.S. 
Randomized controlled trial; 
mailed, self-administered QuIC  
Men with prostate cancer  (n=71) 
willing to enroll in actual biobank  
McCarty et al., 
2008, U.S. 
Qualitative; focus group (Focus 
Group Series 3) 
Potentially eligible biobank subjects 
(n=21)  
McCarty et al., 
2007, U.S. 
Mailed, self- administered QuIC  Random sample of actual biobank 
participants (n=924) 
McCaughey et al., 
2016, Australia 
Retrospective survey: mailed/ e-
mailed, 35-item questionnaire with 
14 questions re: understanding 
Patients and controls (n=141) who 
actually donated a biospecimen for 
ophthalmic research 
McGraw et al., 
2012, U.S. 
Qualitative; cognitive interviews 
evaluating written versus video 
informed consent  
Patients  and community members 
(n=43) making  hypothetical biobanking 
decision 
Merz & Sankar, 
1998, U.S. 
Descriptive survey  Prospective jurors (n=99) making 
hypothetical decision 
Moutel et al., 2001, 
France 
Self-administered questionnaire  Patients (n=51) enrolled in actual 
biobanking study 
Ormond et al., 
2009, U.S. 
Qualitative & Quantitative; 
interviews & QuIC 
Actual biobank participants (n=200)  
Panoyan et al., 
2008, U.S. 
Survey; self-administered 
questionnaire  
Participants (n=151) in actual genetic 
study  
Petersen et al., 
2014 
Belgium, 
Germany, & UK 
Self-administered questionnaire  Female breast cancer patients in 
Belgium (n=152), Germany (n=122), 
and UK  (n=122) 
Rahm et al., 2013, 
U.S. 
Self-administered questionnaire Donors and refusers (n=203)  to  
hypothetical  biobank 
Robinson et al., 
2013, U.S. 
Randomized trial; interview & 
questionnaire 
Individuals (n=229) recruited into actual 
studies  
Roessler et al., 
2015, U.S. 
14 question quiz or semi-structured 
interview (self-rated understanding 
only) 
Research volunteers and patients 
(n=480) being asked to enroll in actual 
biobank 
Shelton, et al., 
2015, U.S. 
Intervention study; experimental 
post-test only;  
in person, self-administered 
questionnaire  
Visitors (n=134) in waiting rooms; 
hypothetical decision to donate 
biospecimen of family member  
Simon et al., 2015, 
U.S. 
2 x2 experimental design; 
prospective randomized study 
/online survey, QuIC 
Patients (n=200) approached for 
enrollment into an actual biobank  
Toccaceli et al., 
2009, Italy 
Mailed, self-administered survey Participants (n=99) recruited from a 
twin registry and radio ads for actual 
genetic study 
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Chapter 3 A qualitative study examining mothers’ decisions to donate their 
newborns’ blood spots for research  
Introduction 
 Residual dried blood spots (rDBS) are blood specimens that remain after legally required 
newborn screening (NBS) is completed on the nearly 4 million infants born annually in the 
United States.  The rDBS are frequently stored and used for research, often without parental 
consent (Lewis, Goldenberg, Anderson, Rothwell, & Botkin, 2011).  The collection of human 
biological specimens for future, unspecified, research (i.e. biobanking) has become a widespread 
practice (Henderson et al., 2013).  By retaining, storing, and distributing rDBS, newborn 
screening programs, managed by state departments of health, are a major source of pediatric 
biospecimens for research.  This research has led to important medical advancements, for 
example, in pediatric cancer research (Zhang et al., 2015), however, with these advancements 
come new ethical issues (e.g. genetic privacy and moral risk) (Hens, Nys, Cassiman, & Dierickx, 
2009).  
 Taking note of ethical concerns, in 2010, the Michigan Department of Health and Human 
Services (MDHHS) was the first to adopt a broad research consent process as part of NBS that 
occurs about 24 hours after birth (Langbo, Bach, Kleyn, & Downes, 2013).  However, because 
broad consent provides few details about future research it may not provide adequate information 
for informed decision-making (Hofmann, 2009) and thereby could contribute to decisional regret 
and moral distress (Harmon, 2010).  While obtaining permission to use rDBS for research is 
laudable and congruent with ethical principles, it is also essential to determine whether mothers 
have adequate information, knowledge, and understanding of biobanking to make an informed 
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choice. As NBS and rDBS research occurs globally, this concern has international implications 
(Therrell et al. 2015). 
Background 
Genetic Privacy 
 It is important that individuals considering a donation to a biobank understand the 
potential risk of a breach of genetic privacy. Deoxyribonucleic acid or “DNA” in biospecimens 
reveals individuals’ unique attributes and genetic predispositions to a host of diseases, including 
many that carry potential, social stigmas (e.g. schizophrenia, alcoholism) (Rothstein, 2010). 
Unwanted exposure of private genetic information may cause personal embarrassment, distress, 
or discrimination (e.g. employment, insurance, or social) despite partial protective legislation 
(Genetic Information Nondiscrimination Act of 2008; Rothstein, 2010).  Because DNA is unique 
to each human, removing identifiers may not fully protect genetic privacy (Rothstein, 2010).  
Moral risk  
 Because the intended research uses of rDBS are often unspecified, alignment with 
personal values may be unclear.  This lack of clarity may precipitate a moral risk, defined as the 
possibility that biospecimens may be used in research activities misaligned with the parents’ (or 
donors’) personal, religious, or cultural values (Rothstein, 2010; Tomlinson, Kaplowitz, & 
Faulkner, 2014). Without specific (or in some cases any) consent, rDBS have been used to study 
issues such as maternal cocaine and tobacco use (Henderson et al., 1997; Spector, Murphy, 
Wickham, Lindgren, & Joseph, 2014). A recent literature review (Eisenhauer & Arslanian-
Engoren, 2016) examining religious values and biobanking decisions identified several religious 
concerns related to biobanking including blood storage, cloning and genetic analysis.   
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Further, rDBS have been used to study birth defects and to develop new techniques for 
prenatal genetic diagnoses (MDHHS, 2017; Nelson et al., 2001). Research from Canada and the 
United Kingdom demonstrates that advances in prenatal genetic testing have contributed to an 
increase in abortions due to the presence of fetal anomalies (Liu et al., 2002; Wyldes & Tonks, 
2007). While some may view such testing as promoting parental choice, others view abortion as 
morally inconsistent with their personal and religious values (Pew Research Center, 2014).  
Theoretical Framework  
 Marteau et al.’s (2001) Multidimensional Measure of Informed Choice (hereafter: 
MMIC) was the theoretical framework for this study (Figure 1). The main concepts are 
knowledge, attitudes, and the participation decisions (i.e. agree or decline).  Knowledge is 
defined as participants’ understanding of key information about a topic, including risks, deemed 
essential by professional consensus for making an informed choice.
 
 Attitudes are value-based 
judgements about facts and information.  In this model, each concept has two possible 
dichotomous outcomes; knowledge may be good or poor; attitudes may be positive or negative, 
and the participation decision may be yes or no.  According to the Marteau et al. (2001, p. 100) 
definition of informed choice “one that is based on relevant knowledge, consistent with the 
decision-maker's values and behaviourally implemented” only two different combinations of 
knowledge, attitudes and participation decisions are considered informed choices. All other 
outcomes are uninformed choices (Table 5). While the MMIC has often been used in studies 
about prenatal testing decisions (Marteau et al. 2001; Piechan et al. 2016; van den Berg, 
Timmermans, ten Kate, van Vugt,  & van der Wal, 2006), this is the first study, to our 
knowledge, to use it to guide the examination of mothers’ decisions about donating newborns’ 
blood spots. 
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Aim 
This paper presents the qualitative component of a larger triangulated study (Eisenhauer, 
2018) conducted to investigate factors influencing mothers’ decisions to donate their newborn’s 
rDBS to the Michigan BioTrust for Health, the program of MDHHS charged with oversight of 
the research use of rDBS (Langbo et al., 2013). The primary aims of this study were to describe 
mothers’ knowledge and values and experience of the consent process and examine how they 
influenced the decision. The specific research questions were:  
1. What do mothers know about biobanking at the time of the consent process for the 
BioTrust?  
2. How do personal and religious values influence mothers’ decisions to donate their 
newborn’s blood spots for research?  
3. Does the current consent process for the BioTrust provide adequate information and 
opportunity for mothers to make an informed choice?  
Design 
A qualitative descriptive design
 
(Sandelowski, 2010) was used to identify factors that 
influence mothers’ decisions regarding donating their newborn’s rDBS for research. Factors 
included the mothers’ knowledge and values, the context of the post-partum unit, and their 
overall experience with the consent process.   
Ethical considerations  
Approval to conduct the study was obtained from the university institutional review 
board (IRB).  Mothers were free to stop the interview at any point or not answer particular 
interview questions. No names were included on audiotapes or transcripts to ensure complete 
confidentiality of the participants. No incentives were offered for participating in the interviews 
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Participants  
Potential participants were recruited using a convenience sample of mothers who had 
given birth within the previous 24-hours and had not yet been approached regarding NBS.  The 
PI (EE) shadowed the staff member responsible for obtaining BioTrust consent (i.e. “the 
consenter”) on the mother/baby unit.  The same consenter was observed for all 29 consent 
interactions.  When the consenter approached each mother to explain NBS and the BioTrust, she 
also explained the PI’s presence. Verbal permission from each mother was obtained for 
observation of the BioTrust consent process. After the mother rendered a decision about the 
BioTrust, the mother was asked to participate in a brief semi-structured interview regarding her 
decision. To be eligible to participate in the semi-structured interview, mothers had to be: (1) 
≥18 years of age, (2) able to speak English, (3) seen within a 24-hour window of rendering the 
decision of interest, and (4) willing to be audiotape recorded.  Once eligibility was determined, 
the study was explained in detail and written informed consent was obtained.  Interviews were 
conducted in the mother’s hospital room at that time or later the same day.  Family members 
(e.g. newborn’s father) who were present were allowed to stay with participant permission and 
were made aware the interview would be audiotaped.    
Data Collection 
Observations  
 Passive participant observation was used to collect data on (1) the physical setting in 
which the consent discussion occurred, (2) informational materials provided, (3) individuals 
present in the room during the consent and interviews, (4) activities and interactions, and (5) 
non-verbal behaviors to emphasize the importance of contextual factors of the post-partum 
period during the BioTrust consent process.  
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Semi-structured interviews  
An interview guide was developed (Table 6) using information in the BioTrust brochure
 
(MDHHS, 2015), essential biobanking informed consent topics (Beskow, Dombeck, Thompson, 
Watson-Ormond, & Weinfurt, 2015) and concepts in the MMIC.  Content validity was 
established by team members with expertise in informed consent (ART) and maternity care (i.e., 
certified nurse midwife [LKL]).  The interview guide was pilot tested with five mothers.  
Additional questions were asked at the completion of the five interviews to elicit feedback about 
the interview process and to assess if anything asked was unclear.  As no suggestions for change 
were provided, these five interviews were included in the final sample.   
 Following the consent process mothers were interviewed to examine their understanding 
of the biobanking information provided and experience with the consent process. Knowledge 
was assessed by asking each participant to describe her understanding of the blood spots, 
newborn screening, the BioTrust, and biobanking. Next, each mother was asked to describe the 
informed consent process that had just occurred (e.g. who came in the room? what were you 
told?).  Each mother was asked to reflect on questions or concerns she may have had during the 
decision-making process, whether her questions were answered, and if any additional 
information may have been helpful.  Each mother was then asked to repeat her decision and 
describe why she agreed or declined to donate her newborn’s blood spots for research and what 
was important to her in making the decision. Lastly, each mother was asked to describe any 
personal experiences or personal or religious values she thought may have influenced her 
decision (Table 6).  At the end of each interview, each mother was given an opportunity to 
provide any additional thoughts or descriptions of their experience. Demographic data including 
age, education, race, religion, insurance status and parity were also collected. After confirmation 
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with the mother that she had no additional information to share, the interview was considered 
complete. The observations and interviews were conducted over four days from October to 
November 2016.  
Data Analysis 
  The data were analyzed using qualitative content analysis as described by Elo & Kyngäs, 
(2008). Steps included: (1) preparation, (2) organizing, and (3) reporting the results. First, 
preparation included verbatim transcription of the audiotaped interviews (EE). This involved 
dwelling with and scrutinizing the data,  accomplished by listening multiple times to each 
interview as part of the transcription process, and then by reading, re-reading, and abstracting the 
interview transcripts (EE and CAE). Next, initial codes were developed based on categories in 
the MMIC framework and interview questions (e.g. knowledge, attitudes, and decisions), and 
keywords and phrases. Narrative data were extracted from the transcripts, organized in tables, 
reviewed, and iteratively compared.  The unit of analysis was the collective experiences of the 20 
mothers who participated in the qualitative interviews. Data matrices were then created to 
compare and contrast responses and demographics of mothers who decided to donate or not 
donate their newborn blood spots. 
 Responses to knowledge questions were classified as either good (+) or poor (-) by two 
coders (EE and CAE).  Responses consistent with factual materials (e.g. per the BioTrust 
brochure) were classified as good knowledge whereas, inconsistent responses or statements such 
as, “I do not know” were classified as poor knowledge.  Similarly, attitudes were classified into 
positive and negative categories. Favorable, optimistic thoughts or feelings toward blood spot 
research were characterized as positive attitudes, while negative attitudes were marked by 
suspicious thoughts or feelings toward such research. Using the MMIC definition of an informed 
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choice, there were only two possible combinations of knowledge, attitude and donation decisions 
that would constitute an informed choice. Option one was when a mother had: a) good 
knowledge about the BioTrust and biobanking, b) a positive attitude toward rDBS research, and 
c) agreed to donate her newborn’s rDBS.  The other option was when a mother had: a) good 
knowledge about the BioTrust and biobanking, b) a negative attitude toward rDBS research, and 
c) declined to donate her newborn’s rDBS (Figure 1).  Choices based on poor knowledge and/or 
attitudes incongruent with decision-making, were classified as uninformed choices per the 
Marteau et al. (2001) framework (Table 5).   
Rigor 
 Trustworthiness of the data was reinforced by the use of audiotape and subsequent 
verbatim transcription of the interviews.  Participants’ views were confirmed through informal 
member checking and probes used during the interviews to clarify statements (Polit & Hungler, 
1999).  The sample size was deemed adequate after the fourteenth interview as determined by 
data saturation, the point when new themes stop occurring and established themes continue to 
repeat (Guest, Bunce & Johnson, 2006; Polit & Hungler, 1999). Inter-rater reliability was 
established using the approach of Miles and Huberman (1994) (number of agreements divided by 
total number of agreements and disagreements).
 
Codes and themes were iteratively discussed, 
defined, and revised as needed between two coders (EE and CAE).  Two evaluations of 
biobanking knowledge were changed from good to poor. Themes of “altruism” and a “pro-
research attitude” were merged into “beneficence” and “perception of limited risk” and 
“concerns about use and privacy” were changed to “level of perceived risk”.  Discordance was 
reconciled by further discussion and 100% consensus was reached. 
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Results 
Observation of BioTrust Consent  
 The BioTrust consent process was observed 29 times and was estimated to be, on 
average, 5 minutes in length.  
 Physical setting.  The physical setting for the BioTrust consent process was private 
rooms on the mother/baby unit of a large, urban, academic medical center; the mother/baby unit 
has 50 private maternity rooms and delivers nearly 4,000 newborns each year.  
 Informational materials. At our institution, mothers are given a folder of information at 
admission, including brochures on NBS
 
(MDHHS, 2015b) and the BioTrust (MDHHS, 2015).  
These folders were observed to be present in the mother’s room during the consent process. A 
detailed review of the brochure materials with the mother during the consent process was not 
observed; however, the consenter did verbally reference them by saying “there’s a pamphlet in 
your folder…” during the observation period.  Prior to checking a yes or no box to indicate a 
participation choice, each mother looked at the BioTrust consent form (MDHHS, n.d.), that 
summarizes key information on the back of the newborn screening blood spot card.  However, it 
is unknown the extent to which mothers actually read or understood the information.  A detailed 
comparison of elements of informed consent for biobanking (Beskow et al., 2015, Joffe, Cook, 
Cleary, Clark, & Weeks, 2001, and Protection of Human Subjects, 2009) and information on the 
blood spot card consent form (MDHHS, n. d.) is presented (Table 7).  No in-depth discussions 
with the consenter were observed, nor were informational materials used that explained potential 
moral risks, controversial types of research, or associated biomedical technologies. 
  Individuals present in the room. Family members, especially fathers and newborns, 
were frequently observed in the room with the mother (e.g. fathers were present in 15/20 (75%) 
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interviews).  Mothers identified others present at the time of the BioTrust consent and/or the 
interviews as an aunt, a sister-in-law, and as grandparents. 
 Activities and interactions. Mothers who had given birth the previous day were 
identified from a list, and approached regarding NBS education and potential rDBS donation.  
The consenter arranged her visits with mothers according to time of delivery and approached 
mothers before the heel stick procedure occurred. While the consenter strived to give each 
mother as much time to rest after birth as possible time constraints existed, as NBS must be 
conducted after the newborn is at least 24 hours old, but before leaving the hospital.  
 The same consenter, an unlicensed member of the ancillary staff, was observed for all 
consent interactions. She respectfully introduced herself to the mother by name and job title, and 
explained she was there to talk about NBS.  Next, the consenter asked each mother if she was 
familiar with the newborn heel stick and described the process. She explained six blood spots 
would be collected to screen for over 50 metabolic diseases, often briefly describing examples 
(e.g. PKU and Cystic Fibrosis).  Next, the consenter described the difference between screening 
and research by stating: “The state also wants me to ask if they can use the leftover blood for 
anonymous medical research. The screening is required, but you can say yes or no to the 
research.”  The manner used to present the information and the language used was the same at 
each encounter.  Discussions of risks were not observed.  Mothers tended not to ask questions 
during the BioTrust consent process. Mothers (or fathers) verbally expressed a choice and then 
signed the blood spot card accordingly.   
 Non-verbal behavior. Eye contact, looks, and glances were observed between mothers 
and fathers before responding to the consent question.  If silence was prolonged, the consenter 
prompted the mother by stating, “the blood spots either go to the biobank for research or sit with 
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the state.  It’s up to you”. During one observation, parents contradicted each other’s decision to 
donate: the mother stated she wanted to agree and the father stated he wanted to decline 
donation. Subsequently, the mother declined. 
Semi-Structured Interviews  
 Participant characteristics. Twenty mothers (20/29; 69%) participated in the semi-
structured interviews and nine mothers declined (9/29; 31%). Interviews lasted between 6 to 20 
minutes (median: 8 minutes). The median age of participants was 32 years old (range 23-42 
years), most were multiparous (n=15), with this birth most often being their second child (n=10).  
Three-quarters (n=15) had at least some college or a college degree. Sixty-three percent of the 
mothers identified a religious affiliation and indicated the practice of their faith was important 
(n=12/19, 63%). Of those mothers who identified a religion, the importance of the practice of 
their faith was rated highly (average 8.75 on a 10-point scale; King, Speck, & Thomas, 1995). 
Characteristics of the participants are presented in Table 8. 
 Knowledge. Fourteen (70%) mothers were able to correctly describe knowledge of the 
newborn screening by stating: “…screening for these different diseases and they will tell us if 
our child has them and what we need to do to treat them to prevent certain symptoms” and 
“…check[ing] for different diseases or illnesses that babies could have.”  Conversely, when 
asked to describe the Michigan BioTrust, most mothers’ (16/20; 80%) stated, “I don’t know 
anything about it” or “nothing” about it.  Similar responses were noted when asked to describe 
biobanking.  Most mothers (16/20; 80%) indicated they did not have any knowledge of it and 
stating, “Biobanking? I don’t know” and “Sorry, I don’t know.”  
 Lack of Knowledge and Misunderstandings. Five mothers who declined to donate their 
newborns’ rDBS for research purposes described a “lack of information around the process” and 
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clearly stated “I just really didn’t know anything…about the research part of it so that’s why my 
answer was no”. Mothers described “the inability to get clear information” and their 
unwillingness to “put my child out there” because “I just don’t know a lot of information”.  One 
mother perceived that donation options were not “presented equally”, and described the BioTrust 
brochure as “definitely geared toward you saying yes.” She stated, “making certain options 
harder…becomes alienating”.  
 In addition, four types of misunderstandings emerged from the narrative data, involving 
11 of the mothers.  One mother who declined donation, misunderstood the procedure and said, “I 
just don’t want him to be more uncomfortable”, believing donation would require the newborn to 
have a second heel stick. Two other mothers agreed to donate because they perceived “it’s [the 
university hospital] asking me” and felt “[the university hospital] does a lot of good research…I 
am happy to participate”. Four other mothers who agreed to donate stated since “…it’s totally 
anonymous” and one said, “if it wasn’t anonymous I probably wouldn’t do it…” Five mothers 
indicated a “nurse” entered the room to ask for consent. 
 Attitudes. All of the mothers who agreed to donate their newborn’s blood spots (n=14) 
had attitudes about blood spot research classified as positive. The six mothers who decided not to 
donate had attitudes classified as negative. No choice was inconsistent with the stated attitudes 
about the blood spot research. 
 Personal value of beneficence. Mothers who agreed to donate their newborn’s blood 
spots (n=14; 70%) overwhelmingly described wanting to do “good” and to “help” others. One 
mother said donating blood spots was about “Helping, helping others, finding cure, helping 
finding cure, hopefully”.  Mothers described blood spot donation as a way “… to be socially 
responsible…” and  “…advance medical care…”  Mothers frequently (n=12; 60%) expressed the 
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perception of research as a benevolent act.  One mother said “…research is good. Let’s do that!” 
and two other mothers stated they were “always pro-research”.  Six of these mothers described 
their “love of science” and perception of “research is good” as related to occupational 
experiences (their own or those of newborn’s father) in education, nursing, medicine, and public 
health.   
 Personal assessment of level of perceived risk.   Three mothers who agreed to donate 
blood spots perceived no risk with the blood spot research. One participant stated “They’re not… 
to harm my child, so, why not [participate]!” Nine others who agreed to donate perceived “little” 
or “small” risks and expressed that the research was “low enough risk that I’m not too worried 
about it”. The perception of low risk was often linked to the fact the bloodspots were “leftover” 
and there would not be “an extra prick” for the newborn.  
However, mothers who declined to donate perceived more risk and stated “… it’s private 
information. I don’t want it to go out in public” and expressed concerns the blood spots would be 
used for “commercial reasons…for profit”.  Additional concerns included “any negative 
research” and “uncertainty about how it’s going to be used.”   
 Religious Values.  Six mothers (30%) described religious, spiritual, or moral issues that 
influenced their donation decisions. Two mothers, who agreed to donate, associated “trying to 
help each other” with their religious beliefs.  They stated “[my congregation] really believe in the 
inner connectedness of all livings beings” and “I hope to God they find cures for illnesses.”  Two 
other mothers, who agreed to donate, said: “just don’t clone them” or use the blood spots for 
“anything like immoral, like…abortion”.  A mother who declined to donate stated “…I believe in 
certain things like being Christian for one, and in Christ and all that” and she feared the blood 
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spots may be used for “witchcraft”. Another mother denied that “visions”, (i.e. religious or 
spiritual entities), led her to say no, but stated she declined based on her lack of knowledge.  
 Mothers’ descriptions of consent process.  The majority of mothers (12/20; 60%) were 
able to describe the difference between NBS and the request to use rDBS for research.  One 
mother stated: 
 “She came she came in and …described… the state requires six bloodspots and they do 
 some testing for children…and then…she asked…  if we would be willing to…use the 
 leftover blood spots for research.”  
However, eight mothers were unable to describe the difference clearly.  One mother stated, “She 
just really just asked me if I … want to it get a researched [sic]and I said yes, but I don’t want 
those remaining blood kept”.  
 Four mothers characterized the consent process as “straight forward” or “no big deal” and 
as an “easy decision”.  Two of these mothers reported “details” were not provided, nor were they 
always perceived as necessary. One mother stated,  
 “…I think she didn’t specify more details just because I didn’t ask for them ….  
Two mothers stated the speed at which the decision was made was “… like a one second 
decision!” and “…I made it on the fly!” A third mother stated, “I didn’t think twice of it”.  
 Two mothers specifically reported the brief explanation provided by the consenter to be 
“helpful” in making the decision and that the consenter “kind of went over it a little bit with us.”  
Two other mothers stated they appreciated “having a choice” about donation (one said yes and 
one said no to donation) and three mothers explicitly denied feeling any pressure imposed by the 
consenter to influence their decisions. One said it was “very low pressure… like it was okay 
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either way.” Another one stated she felt “no pressure at all” and the third mother said “it felt 
normal.” However, another mother described that she did not find the process helpful stating:  
 …how can we give informed consent when you’re getting patients who a couple of  
 hours, couple of hours after a birth, when they’ve had all kind of narcotics and drugs, and 
 trauma? And there is somebody in the room every half hour performing some sort of test, 
 and this is just one more test, and again, you are not really informed about your choices.”  
 When asked, “If you were to change your mind about donating what would you have to 
do?”  Four mothers were able to described the process to withdraw from the BioTrust stating 
they would “[use] the internet”, “read the pamphlet”, or “contact the state”.  Eight other mothers 
described it as “telling the lady” or “telling you guys”, while others stated they did not know 
(n=5) or did not understand the question (n=3). 
 Demographics and Decisions.  A total of 14 mothers agreed to donate their newborn’s 
blood spots to the BioTrust and six declined. Mothers who self-identified as of white race tended 
to agree to donate, while mothers who self-identified as of a non-white race were split in their 
decisions (Table 8).  Additionally, mothers who declined to donate tended to be of younger age, 
(in their twenties), compared to mothers who agreed to donate rDBS, who were mostly in their 
thirties or over forty years of age. Twelve mothers (12/19; 63% of those who answered 
demographic questions) reported a religious affiliation (i.e. Christian, Muslim, or Unitarian).  
Five out of twelve (42%) mothers who indicated a religious affiliation declined to donate their 
newborn’s rDBS, whereas all of the seven mothers who indicated no religious affiliation agreed 
to donate their newborn’s rDBS.  Education, insurance status, and number of births did not seem 
to be exclusively associated with any particular donation decisions (Table 8).  
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 Classification of choices.  Based on the MMIC four mothers (20%) made an informed 
choice: a choice congruent with both (a) possessing relevant knowledge and (b) consistent with 
personal attitudes toward blood spot research.  Sixteen mothers (80%) lacked the relevant 
knowledge to make an informed choice (Table 9 & 10).  Informed choices included three 
mothers who agreed to donate and one who declined.  Only three of the four mothers who made 
an informed choice were willing to answer demographic questions. All three of these mothers 
were in their 30s, had at least some college education, and identified a religious affiliation. Two 
had private insurance and one had public insurance (i.e. Medicaid). Two mothers were 
multiparous and one a first time mother; fathers were present in two out of four instances of 
informed choice. All mothers indicated they were fairly confident with their decisions (Table 8).  
Discussion 
 This study provides insight into the knowledge, attitudes, and decision-making of 
mothers faced with the choice of whether or not to donate their newborn’s blood spots for 
research purposes.  The majority of mothers (n=16, 80%) made the decision without adequate 
knowledge of the Michigan BioTrust or biobanking.  These decisions failed to reach the 
threshold of an informed choice. Findings were consistent with the current literature indicating 
biobanking participants lack understanding of key elements of informed consent (Eisenhauer, 
Tait, Rieh, & Arslanian-Engoren, 2017)
 
and that low knowledge scores contribute to uninformed 
decisions about prenatal testing (Marteau et al. 2001; Piechan et al. 2016; van den Berg et al. 
2006), and declining vaccinations for children (Lehmann, de Melker, Timmermans, & Mollema, 
2017).  This lack of knowledge was also exhibited in the form of misunderstandings.  Of 
concern, 11 mothers made decisions influenced by one or more of four different 
misunderstandings, one of which was perceived use of rDBS as anonymous. When used for 
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research, rDBS are de-identified and coded (MDHHS, 2015); but do not meet the Food and Drug 
Administration’s (2008) definition of anonymous biospecimens as “never labeled with personal 
identifiers when originally collected, neither is a coding key generated” (p.6).  While the consent 
form states the rDBS are coded, the consenter incorrectly characterized the identifiability of the 
rDBS as anonymous, which may have contributed to this misunderstanding.  
Information & Attitudes 
Decisions about donating blood spots were often based on attitudes toward biomedical 
research in general.  Many of the mothers interviewed in this study expressed a belief that all 
research was good and beneficial.  This may have influenced their decision to donate, a finding 
that calls for further research to evaluate how mothers’ assess the credibility of the presented 
information (Rieh, 2002). However, two mothers who agreed to donate rDBS expressed moral 
caveats on research involving abortion and cloning, indicating perceptions of moral risk. One 
held the misperception that the request for rDBS was emanating from the hospital, a trusted 
institution in the community, even though the request was not from the hospital.  Thus, it will be 
important to clarify in the written material and during verbal discussions that the request for 
rDBS is coming from MDHHS, and not the hospital, so that mothers have accurate information 
on which to base their donation decision. The six mothers who declined to donate perceived 
higher risks to personal values (e.g. privacy and uses). Consistent with other research, religious 
values were found to both encourage and discourage donation (Eisenhauer & Arslannian-
Engoren, 2016; Hassona, Ahram, Odeh, Gosh, & Scully, 2016).  When a religious influence was 
present, those who agreed to donate tended to link altruism and the pursuit of health with their 
religious beliefs, and those who declined tended to link moral concerns to religious prohibitions.  
Process and Context 
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  Five mothers in this study perceived the consenter to be a nurse, even though she was an 
ancillary staff member and she did not introduce herself as a nurse.  The credentials (or the 
perception of credentials), communication skills, and actions of the consenter may influence 
understanding and decision-making about biobanking research participation (Eisenhauer et al., 
2017).  Because of the high degree of public trust in nurses (Norman, 2016), perceiving the 
consenter to be a nurse may have influenced mothers’ decisions to donate their newborn’s rDBS 
for research purposes.  While trust in the consenter may be a motivating factor and lead an 
individual to participate in biobanking, trust should not be conflated with objective 
understanding of information (e.g. risks and benefits) (Fisher & Fisher, 2000).  Hoeyer  (2003) 
showed that patients’ trust in nurses is so strong that it may impede rational deliberation during 
biobanking consent. However, in contrast, Cervo et al. (2013) found participants to have a good 
understanding of biobanking after initially speaking with a physician, and then a biobank nurse 
or biologist; adequate levels of understanding of the informed consent information were reported 
among participants. 
  Further, the manner in which the consenter presented the choice may also have 
influenced mothers’ decision-making. While her approach was friendly, it was also routine, brief, 
and observed to elicit only a yes or no response, as opposed to asking in a manner to create an 
opportunity for a more open discussion. During the observed consent process, no examples of 
specific types of research were provided during the interactions and no values-clarification 
techniques were observed being used (e.g. asking: how do you feel about biobanking?).  Instead, 
it appeared that the choice relied on a consumer information model of consent in which basic 
information is provided and the individual is left alone to make an autonomous choice (Gadow, 
1990).  A better approach might be to follow a model of shared decision-making and existential 
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advocacy (Gadow, 1990) where evidence and information is openly shared, participant values 
are clarified, and the participant “is supported to consider options, to achieve informed 
preferences” (Elwyn et al. 2012, p.1361).  Extended discussion with a knowledgeable person is 
the most efficacious intervention to aid understanding of consent information (Flory & Emanuel, 
2004; Nishimura et al., 2013). 
One possible explanation for the observations may be that while the MDHHS provides 
some in-person and online BioTrust consent training to birth hospital personnel (Langbo et al., 
2013), it appears to be minimal. An online flyer (MDHHS, 2018) lists only eight brief steps for 
obtaining consent (i.e. “Provide BioTrust consent brochure. Ask parent to read. Answer any 
questions. If a parent has more questions, contact BioTrust Coordinator. Ask parent to mark their 
decision. Collect parent signature. Return white copy to state lab. Give pink copy to parent.”) 
Additional educational efforts include an online video training describing the process of 
obtaining consent that includes a certificate of completion option for the consenter (MDHHS, 
2016). While this is commendable, it raises many concerns.  In particular, it remains unclear if 
this training is optional or required, how compliance is monitored, how evaluation is conducted, 
or if there are minimum educational requirements for consenters.   
 Although the blood spot card consent form was created by MDHHS in collaboration with 
the Office of Human Research Protections (OHRP) to address all required elements of the 
consent process (Rothwell et al., 2017), it appears the card was written in a generic manner 
without attention to the specifics of biobanking or donating rDBS.  The form does not clearly 
explain that newborn screening will still be conducted, and that the pediatrician will still receive 
results, even if parent(s) decline research participation. As such, the distinction between newborn 
screening and experimental blood spot research may not be clear.  The card does not address any 
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medical or lifestyle information about the parents or the newborns that may be linked to the 
rDBS from other state databases or registries (e.g. birth certificates; see Korzeniewski et al., 
2010). The only risk listed is that the blood spot could be identified.  The card does not address 
the risk of participating in research that may be incongruent with personal or religious values 
(i.e. moral risks).  The issue of using rDBS to develop commercial for profit products is not 
addressed on the blood spot card, although identified frequently as a value-based concern of 
biobank participants (Eisenhauer et al. 2017; Eisenhauer & Arslanian-Engoren, 2016) and 
mothers in this study.  Comparisons are considered essential pieces of information to aid 
understanding (Brehaut, 2012).  Key terms (e.g. DNA, low risk) are not explained or defined and 
the word “experimental” is not used.  
 A recent focus group study of 69 participants in three states reported individuals found 
information on the blood spot card confusing (Rothwell et al., 2017).  The lack of understanding 
among participants in this study about the level of identifiability of the blood spots was similar to 
findings of Rothwell et al. (2107) where focus group participants were also confused about the 
level of identifiability of the blood spots after reading the information on the consent card.  
Participants in Rothwell et al. (2017) wondered why the benefit section does not mention any 
possible benefits of the rDBS to society as a whole. In addition, although possible injury is not 
listed as a risk of participation, the card oddly mentions a number to call in case of a research 
related injury (Rothwell et al., 2017).  Without comparisons or specific research examples 
participants had difficulty understanding what types of research may be conducted on blood 
spots. Specific examples were desired by mothers in this study and are requested by the general 
public (Rothwell et al, 2017). Other common elements of biobanking consent (Beskow et al., 
2015) such as return or research results, re-contact for future studies, and the role of cells, DNA 
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and/or genetics are not addressed on the consent card. While key elements are further explained 
in the BioTrust brochure, several mothers in our study reported not having read it; nor was 
information from it discussed with the mother by the consenter.   
 The context of the postpartum period also influenced information use and decision-
making as described by participants in this study.  Fathers were an important influence on 
mother’s decisions to donate their newborn’s blood spots for research. During the interviews, 
fathers frequently asked or answered questions, even though research questions were intended 
for and directed to the mother. It was observed that decision-making about blood spot donation 
was often a joint decision between the parents of the newborn.  While fathers’ level of 
biobanking knowledge and involvement in this decision was not specifically assessed in this 
study, it should be required, as they both have contributed to a newborn’s DNA (Baumann, 
2001). 
 Mothers described being sleep-deprived, fatigued, under the effect of medication or in 
pain, and were observed to be preoccupied with their new baby. There are a myriad of decisions 
that need to be made during the postpartum period, including decisions about newborn care, pain 
medication, breastfeeding, and male circumcision (Torres & De Vries, 2009).  Others have found 
the routinizations of consent for such decisions may impede informed consent (Lowe, 2004; 
Press & Browner, 1997). Patients’ values and ethical dilemmas are often overlooked during 
consent for these procedures, and the potential emotional consequences of the decisions are often 
not fully explained (Lowe, 2004; Press & Browner, 1997).  It seems the same may hold true for 
the BioTrust decision, in this often physically and emotionally overwhelming context. This 
provides support for moving information and education about rDBS research out of the 
postpartum environment and into the prenatal setting (American College of Obstetricians and 
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Gynecologists, 2015; American Academy of Pediatrics, Newborn Screening Authoring 
Committee, 2008). 
Limitations and Strengths 
 There were three limitations to this study: (1) the small sample size at a single institution 
(2) adaptations and limitations of the MMIC, and (3) the potential for the Hawthorne effect.  The 
study sample was a small, convenience sample derived from a single data collection site, where 
only one consenter was observed which limits the generalizability of results to the larger 
population. However, data saturation was achieved, adding strength to its adequacy and validity 
(Guest, Bunce & Johnson, 2006; Polit & Hungler, 1999). The novel application of MMIC to data 
on mothers’ decisions about donating their newborns’ blood spots for research was a strength of 
the study. However, the MMIC attributes an informed choice to only three categories: 
knowledge, attitudes, and participation. An informed choice may be more complex and involve a 
component of deliberation (van den Berg et al. 2006), not captured in the MMIC. In addition, 
dichotomized categories likely reduced the granularity in the interview data.  Further, the MMIC 
was originally used with quantitative scale data and verified with qualitative responses. 
However, our qualitative interviews produced rich, detailed data that captured the mothers’ 
decision-making process as it occurred. The examination of actual, real-time decisions that 
occurred in their natural environment on the post-partum unit was a noted strength of the study, 
as was the ability to observe the effects of context on decision-making.  Lastly, despite efforts by 
the PI to be as unobtrusive as possible during the observations of the consent process, one cannot 
rule out the potential for a Hawthorne effect. The consenter knew she was being observed which 
may have influenced her behavior during the consent the process (Polit & Hungler, 1999).   
82 
 
Policy Implications 
 Based on findings from this study, four policy recommendations are put forth: (1) 
Information provided to parents about research on rDBS must be accurate, comprehensive, and 
include ethical implications of biobanking. Positive and potentially controversial research 
examples must be provided; (2) Evidence-based decision-aids should be developed to 
supplement verbal interaction between the consenter and the potential participant in biobanking 
consent discussions. (3) The consenter should be required to annually complete and document 
appropriate training to conduct informed consent discussions including training form MDHHS 
on rDBS research, communication skills training, and formal human subjects’ training, such as 
that provided by the National Institutes of Health (NIH, 2018). (4) Education about NBS and 
rDBS research should begin at the time of the prenatal visits.  
 Provision of information about the moral implications of biobanking has been found to 
influence decisions (Tomlinson, Kaplowitz, & Faulkner, 2014; Tomlinson, De Vries, Ryan, Kim, 
Lehpamer, & Kim, 2015). Implementing standardized tools designed to elicit and clarify values 
to aid decision making will help to provide value-based, tailored information to each potential 
participant. Decision aids are effective in improving the quality of other preference-based 
healthcare decisions (Stacey et al., 2017).  The delivery of complex consent information requires 
advanced communication skills, comparisons, and value-clarification techniques (Brehaut et al., 
2012).  These are skills many nurses possess or could enhance via continuing education.  
Furthermore, the application of nursing theory has been useful in the care and recruitment of 
research subjects (Penckofer, Byrn, Mumby, & Ferrans, 2011).  Studies need to be conducted to 
assess differences in participant understanding based on the credential of the consenter to 
improve the informed consent process. In the meantime, all consenters should at least have 
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training form MDHHS on rDBS research, communication skills training, and human subject 
protection training  Moreover, leading organizations have called for moving these educational 
activities form the postpartum environment to the prenatal setting to provide more time, in a less 
stressful environment for the consideration of complex information (American College of 
Obstetricians and Gynecologists, 2015; American Academy of Pediatrics, Newborn Screening 
Authoring Committee, 2008). While individual level knowledge may be difficult to improve, the 
process and context of the BioTrust consent process may be more amenable to change.  
Conclusion 
 This study examined donation decisions of mothers asked donate their newborn’s rDBS 
for research purposes to the Michigan BioTrust.  While most mothers agreed to donate the blood 
spots, many decisions were based on inadequate knowledge and misunderstandings. Therefore, 
policy changes are needed to re-structure the informed consent process to promote knowledge, 
understanding and to explicate values.  Consenter certification, value clarification techniques, 
and changing the context in which education about NBS and rDBS research occurs, will 
facilitate informed choices. To facilitate a more meaningful informed consent process for 
biobanking decision making, additional research is needed to more fully understand optimal 
content, timing, and delivery of education about NBS and rDBS.   
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Table 5. Marteau et al. (2001) Choice Classifications 
 Good Knowledge  Positive Attitude Donation Decision 
Informed Choices     
  X X 
    
Uninformed Choices   X  
   X 
 X   
 X X  
 X  X 
 X X X 
 =Yes/X=No. Good knowledge=responses consistent with factual materials (e.g. the NBS and 
 BioTrust brochures). Poor knowledge=inconsistent responses or “I do not know”. Positive 
 attitude= favorable, optimistic thoughts or feelings toward blood spot research. Negative 
 attitude = suspicion or opposition toward such research. 
  
85 
 
   Table 6. Examples of interview questions, probes, and categories 
Interview Questions  Probes  Category 
First, please describe to me what you know about the blood 
spots from the newborn screening test? 
What do you understand about 
the blood spots from the 
newborn screening test? 
NBS 
Knowledge 
Please tell me what you know about the Michigan BioTrust.  BioTrust 
Knowledge  
Next, please describe how you were asked for permission to 
donate the leftover blood spots to the BioTrust as you 
experienced it.  
Who asked for your 
permission? What did s/he tell 
you? What happened? What 
kind of information were you 
given?  
Informed 
Consent  
What was your decision about the donating your baby’s blood 
spots to the biobank?  
Did you agree or not agree to 
donate your baby’s blood spot 
to the biobank? 
Donation 
Decision
1
  
What kinds of thoughts, questions, or concerns were in your 
mind as you made your decision? 
 Values/ 
Attitudes  
Do you think your questions answered? How was this done?  By whom or by what 
information? 
Informed 
Consent  
Do you think you were you able to get the information that you 
needed to make the decision? 
 Informed 
Consent  
Is there any additional information that would have been 
helpful to you in making this decision? 
 Informed 
Consent  
If you had more time, would you be willing to find more 
information? 
 Informed 
Consent  
What did you find helpful or unhelpful to you to make the 
decision to donate your baby’s blood spot to the MI BioTrust? 
 Informed 
Consent  
Please tell me about how you chose (yes/no)?  
 
 What was important to you in 
making the decision? 
Values/ 
Attitudes  
What personal experiences, values, opinions or religious beliefs 
of yours do you think may have influenced your decision?  
How did ______affect your 
decision? Can you give me an 
example?  
Values/ 
Attitudes  
 
What have you heard about biobanking?  Can you please describe 
biobanking in your own words? 
Biobanking 
Knowledge  
What is the purpose of the Michigan BioTrust?  Knowledge  
Informed 
Consent  
Next, please describe your expectations about medical research 
involving your child’s genetic information/bloodspots. 
 Attitudes/ 
Values  
Do you have any concerns about medical research involving 
your child’s genetic information/bloodspots?  If yes, please 
explain.   
 Attitudes/ 
Values  
Are there things you would want or would not want the blood 
spots used for?  
Like what? Can you please give 
me an example? 
Attitudes/ 
Values  
On a scale of 1-5 (rating decribed) how would you rate your 
confidence in your decision? 
 Confidence  
If you were to change your mind about donating what would 
you have to do? 
 Informed 
Consent   
*Please complete the following sentence:  
For me, personally, donating (or not donating) my newborn’s 
blood spots for research is_(fill in the blank)____. 
 Attitude  
Anything you would like to add about your experience and 
decision regarding the BioTrust? 
 Summation 
* Question adapted from Marteau et al.; 2001 NBS=newborn screening; 1. 19/20 decisions were observed as they were made.  
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Table 7. Comparison between Elements of Informed Consent for Biobanking and MDHHS NBS Blood Spot Consent Card 
 Consent Element  MDHHS NBS Blood Spot Card Consent 
1 Access to Specimens   “the state lab and research approved by MDHHS” & “researchers” 
2 Alternatives Blood spots “may or may not be used for health research.” 
3 Benefits “Most likely you or your child will not benefit from blood spot 
research.”  
4 Data from Medical 
Record(s) 
Not addressed on card. 
5 Confidentiality “Unused blood spots are stored using a code and not your child's name.” 
“Many steps are taken to protect privacy. Details that could identify your 
child or family are removed before your child's blood spots are given to a 
researcher.”  
6 Contact Person “If you still have questions, please call the Michigan Department of 
Health and Human Services (MDHHS) toll free at 1-866-673-9939.”  
7 Experimental  
Procedures 
“Many types of laboratory methods are used to study biological factors 
like DNA or environmental factors like metals and toxins.”  
8 Injury States “For questions about your research rights or whom to contact in 
case of a research-related injury, please call the MDHHS IRB at 517-
241-1928.”   
9 No Penalty “There is no penalty or loss of benefits for saying no or changing your 
mind.”  
10 Payment/Commercial 
Use 
Not addressed on card. 
11 Purpose “Stored blood spots may be used by the state lab to help ensure that 
newborn screening detects those at risk. Stored blood spots may also be 
used for research approved by MDHHS. Blood spots can only be used 
for studies to better understand disease or improve the public's health.”  
12 Research 
(Awareness) 
“My baby's blood spots may be used for health research through the 
BioTrust” or “My baby's blood spots may not be used for health 
research.” 
13 Re-contact Not addressed on card. 
14 Return of Results Not addressed on card.  
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15 Risks “The risk for using your baby's blood spots in research is that it could be 
identified. This risk is very low. Many steps are taken to protect privacy. 
Details that could identify your child or family are removed before your 
child's blood spots are given to a researcher.”  
16 Role of Cells, DNA, 
Genetics 
Not addressed on card. 
17 Study Duration “The spots are stored forever at a secure site (Biobank) unless you, or 
your grown child, change your mind.” 
18 Study Procedures “Your choice applies to all blood spots collected for newborn screening.”  
19 Voluntary “Participation is voluntary.” 
20 Withdrawal “You can call MDHHS at any time if you change your mind.” 
Sources: Elements of informed consent for biobanking synthesized from: Beskow, Dombeck, Thompson,  
Watson-Ormond, & Weinfurt, 2015, Joffe, Cook, Cleary, Clark, & Weeks, 2001, and  
Protection of Human Subjects, 2009. MDHHS NBS blood spot card consent form (MDHHS, n. d.). 
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Table 8. Characteristics of interviewed mothers 
Age, years  Donation Decision  
Yes (n=14)      No (n=6)*(%) 
  Median 
   Range 
32 
23-42 
34 
25-42 
24 
23-29 
Race n       (%) n      (%) n     (%) 
   Asian 
   Black or African American  
   White or Caucasian 
Other  (Arabic,  mixed-race, other) 
Unknown 
1       (5) 
2       (11) 
12     (63) 
4       (21) 
0       (0) 
0       (0) 
0       (0) 
11    (79) 
3      (21) 
0      (0) 
1     (17) 
2     (33) 
1     (17) 
1     (17) 
1     (17) 
Religion    
Christian  
Muslim  
None  
Unitarian 
Unknown 
6       (32) 
5       (26) 
7       (37) 
1       (5) 
0       (0) 
3       (21) 
3       (21) 
7       (50) 
1       (7) 
0       (0) 
3      (50) 
2      (33) 
0      (0) 
0      (0) 
1      (17) 
Highest level of education completed     
   High School 
   Some College  
   Bachelor’s   
   Master’s  
   Professional Degree (PhD, MD) 
   Unknown 
4       (21) 
6       (32) 
4       (21) 
4       (21) 
1       (5) 
 0      (0) 
1       (7) 
5       (36) 
4       (29) 
3       (21) 
1       (7) 
0       (0) 
3      (50) 
1      (17) 
0      (0) 
1      (17) 
0      (0) 
1     (17) 
Insurance coverage    
Public  (Medicaid) 
Private (Employer sponsored /Self-insured)  
Both  
Unknown 
8    (42) 
10   (53) 
1      (5) 
0      (0) 
5   (36) 
9   (64) 
0   (0) 
0   (0) 
3  (50) 
1   (17) 
1   (17) 
1   (17) 
# of live births (including this baby)    
  1  4     (21) 3  (21) 1   (17) 
  2 10   (53) 7  (50) 3   (50) 
≥ 3 
Unknown 
5     (26)  
0     (0) 
4  (29) 
0   (0) 
1   (17) 
1   (17) 
Confidence in Decision -Average 
(1 uncertain- 5 very confident)  
   
Overall  4.4 4.5 4.2 
*NOTE: n = 19/20; 1 mother declined to answer demographic questions---donation  
decision=no; informed choice=yes. Columns may not total 100% due to rounding. 
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Table 9. Examples of mothers’ responses to questions eliciting knowledge about biobanking, the MI BioTrust, and 
attitudes towards the donation of the newborn’s blood spots for research. 
Knowledge Questions Responses classified as indicating good 
knowledge  
Responses classified as 
indicating poor 
knowledge   
Please tell me what you 
know about the Michigan 
BioTrust. 
…there is a Detroit BioTrust so I read a 
little bit about the Detroit BioTrust and the 
fact that it provides anonymous 
samples…of… the Michigan bloodspots for 
various types of research projects and they 
have to be approved for them to get 
access…  
I actually don’t know 
anything about it [laughs].  
What have you heard about 
biobanking? Probe: Can you 
please describe biobanking 
in your own words. 
….Biobanking isn’t that where they take 
samples of ah blood, hold them over and 
they study it?  And I think they save it 
forever or something like that?  
Biobanking? I don’t know. 
Sorry, I don’t know. 
(What is or) Do you know 
the purpose of the Michigan 
BioTrust? 
…other than just research and to study the 
different, different genetic diseases that are 
present. That’s about what I know.  
I don’t [know].  
Attitude Questions Responses indicating positive attitudes 
towards blood spot biobanking research  
Responses indicating 
negative attitudes 
towards blood spot 
biobanking research  
For me, personally, donating 
my newborn’s blood spots 
for research is _______. 
Rewarding.  Not going to happen!  
 
What kinds of thoughts, 
questions, or concerns were 
in your mind as you made 
your decision? 
…I’m always pro research so… Yeah. And 
I knew that it’s totally anonymous kind of 
thing too, so it’s not it’s like anybody 
knows whose is whose….  
…it’s just that I don’t 
know much about it, so 
well I didn’t …want to put 
something out there and I 
didn’t understand it too.  
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Table 10.  Biobanking Choice Classifications based on Marteau et al. (2001). 
 Good Knowledge  Positive Attitude Donation Decision # of Mothers  
Informed Choices      
    3 
  X X 1 
Uninformed Choices      
  X  0 
   X 0 
 X   11 
 X X  0 
 X  X 0 
 X X X 5 
=Yes/X=No. Good knowledge=responses consistent with factual materials (e.g. the NBS and BioTrust brochures). 
Poor knowledge=inconsistent responses or “I do not know”. Positive attitude= favorable, optimistic thoughts or 
feelings toward blood spot research. Negative attitude = suspicion or opposition toward such research. Adapted from 
Marteau et al. (2001) p. 104. 
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Chapter 4 Measuring mothers’ choices about blood spot donation for research 
Introduction 
 Due to the rapid evolution of genetic and genomic science, it is likely that every 
individual living today will, at some point, be asked to donate biospecimens for research (Wells 
et al., 2014).  However, in order to make an informed choice regarding donation of biospecimens 
for research there must be an understanding of the potential risks and benefits, including threats 
to genetic privacy and personal values and the possibility of life-saving medical advancements 
(Rothstein, 2005).  An informed choice also requires adequate knowledge and consideration of 
personal values relative to the consequences of the decision (Marteau, Dormandy, & Michie, 
2001).  When biobanking consent is obtained, potential participants may be provided with 
minimal information and a consent form that grants research broad latitude for future research 
(i.e. broad consent) (Hofmann, 2009).  However, the provision of basic biobanking information 
alone may not be enough and often fails to satisfy the foundational ethical mandate of informed 
consent. Instead, it is the responsibility of those requesting biospecimen donations to ensure that 
potential participants have sufficient knowledge to make an informed choice (Protection of 
Human Subjects, 2009).  
 A recent literature review revealed that many individuals have difficulty understanding 
biobanking information (Eisenhauer, Tait, Rieh, & Arslanian-Engoren, 2017). To date, it has 
been difficult to develop effective interventions to facilitate informed choices, in part because of 
empirical research related to participants’ understanding of informed consent for biobanking 
lacks standard definitions, instruments, and theoretical frameworks, making comparison across 
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studies difficult  (Eisenhauer et al., 2017; Sand, Kaasa, & Loge, 2010).   Therefore, this study 
was designed to begin to address these deficits by (1) defining and measuring key variables (i.e. 
knowledge, attitudes, and informed choice) with standardized  instruments and (2) using an 
established framework--- the multidimensional measure of informed choice (Marteau et al. 2001) 
to assess participant understanding of biobanking and determine the proportion of informed 
choices made. The findings will be used to inform future interventions aimed at improving the 
informed consent process for biobanking.  
Background 
Newborns’ blood spots  
 Newborn screening (NBS) programs administered by state departments of health have 
become “huge biorepositories [biobanks] of blood samples from all newborns in the USA” 
(Tarini & Lantos, 2013, p. 82).  Unless a parent objects for religious reasons, all newborns in the 
United States (U.S.) (approximately 4 million annually) are required to undergo newborn 
screening (NBS).  This involves blood drawn from a newborn’s heel and collected on filter paper 
to screen for treatable metabolic and genetic disorders, which if left undiagnosed or untreated 
can cause permanent disability (Baby’s First Test, 2017).   While few doubt the importance of 
early detection of treatable diseases, some question whether NBS screening programs have 
expanded too far beyond their original mission (Botkin & Rothwell, 2016; Lewis, Goldenberg, 
Anderson, Rothwell, & Botkin, 2011).  Many states now retain, store, and distribute the residual 
dried blood spots (rDBS) for research after NBS has been completed, often without parental 
consent (Botkin & Rothwell, 2016; Lewis et al. 2011; Olney et al. 2006).  As such, these 
biobanks have become one of the largest sources of pediatric biospecimens available for research 
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purposes; California has 16 million specimens and Michigan 5 million specimens, dating back to 
the 1980s (McGreevy, 2015; MNB: Michigan Neonatal Biobank, n.d.).   
State policies vary about whether parental permission is required to use newborns’ rDBS 
for research (Lewis et al., 2011).  Because rDBS contain deoxyribonucleic acid (DNA) and 
because the sequencing of DNA reveals the unique genetic pattern of each newborn, the storage, 
retention, and research practices that use rDBS raise ethical concerns about privacy and values 
(Hens, Nys, Cassiman, &  Dierickx, 2009).  Studies show that parents want to be asked 
permission for, and feel they have the right to decline the use of their newborn’s biological 
material for research purposes (Tarini et al., 2009; Botkin et al., 2012; Thiel et al., 2014).  
Lawsuits filed over parents’ privacy concerns have resulted in changes in state policies and the 
subsequent destruction of millions of blood spot cards (Carmichael, 2011; Couzin-Frankel, 2009; 
Cohen et al., 2010).   
Michigan  
 In 2009, the Michigan Department of Health and Human Services (MDHHS) proactively 
created the Michigan BioTrust for Health (i.e. the “BioTrust”) to operationalize policies 
regarding the storage and research use of newborn rDBS leftover from state mandated, newborn 
screening programs (Langbo et al., 2013). Currently, three advisory boards inform policy 
development: Community Values Advisory Board (CVAB), Scientific Advisory Board (SAB), 
and the board of directors of Michigan Neonatal Biobank (MNB) (Langbo et al., 2013).  In 2010, 
MDHHS implemented an opt-in parental consent process, conducted within 24-hours of birth in 
connection with NBS, for parents considering donation of their newborns’ rDBS to the BioTrust 
for research purposes (Langbo et al., 2013).   
Areas of Consensus  
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 While there is much debate about the type and scope of consent for biobanking 
(Hofmann, 2009), two areas of consensus exist: (1) Individuals should have sufficient knowledge 
and understanding of biobanking in order to voluntarily donate their (or their newborn’s) 
biospecimens for research purposes (Greely, 1999; Hofmann, 2009; Sheehan, 2011); and (2) 
there are specific elements of biobanking, including risks, vetted by experts, that a person should 
understand in order to participate (Beskow, Dombeck, Thompson, Watson-Ormond, & Weinfurt, 
2015; Wells et al., 2014).   
  A consent procedure should facilitate knowledge and understanding to help a person 
make an informed, voluntary choice, and not simply provide legal protection to the state or 
convince a person to participate (Marteau et al., 2001; Raffle, 2001; Roth, Meisel, & Lidz, 1977). 
Without accurate knowledge and information, it may be difficult for an individual to deduce 
alignment with their values and rendered decisions may be misaligned. While the state of 
Michigan’s early adoption of an opt-in consent process for storage and research use of the blood 
spots is commendable, it is remains unknown if these biobanking decisions are informed choices 
(Marteau et al., 2001).  
Theoretical Framework  
 The theoretical framework for this study was the Multidimensional Measure of Informed 
Choice (MMIC) by Marteau et al. (2001) (Figure 1). The principal concepts of this framework 
are knowledge, attitudes, and the participation decision.  In the framework, knowledge is defined 
as participants’ understanding of key information about a topic, including risks, deemed essential 
by professional consensus for making an informed choice. Attitudes are value judgements about 
facts and information. In this model, each concept has two possible dichotomous outcomes; 
knowledge may be good or poor; attitudes may be positive or negative, and the participation 
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decision may be to agree or decline to participate. According to the Marteau et al. (2001, p. 100) 
informed choice is defined as “one that is based on relevant knowledge, consistent with the 
decision-maker's values and behaviourally implemented” only two different combinations of 
knowledge, attitudes and participation decisions are considered informed choices (Figure 1).  All 
other outcomes are uninformed choices (Table 5).  
Aims 
 The purposes of this study were to: (1) describe mothers’ of newborns level of 
biobanking knowledge, attitudes, and personal and religious values, using established measures; 
(2) determine the influence of these factors on mother’s decisions to donate their child’s residual 
blood spots for research purposes; and (3) evaluate the proportion of mothers’ who make an 
informed choice.  
Design 
 A larger methodologically triangulated study was conducted to describe the influence of 
mothers’ biobanking knowledge, personal values, and perceptions of the consent process on their 
decisions to donate their newborn’s rDBS for research purposes and determine the proportion of 
informed choices (Eisenhauer, 2018).  A qualitative descriptive study was conducted and found 
participants (n = 20) lacked knowledge of the BioTrust and biobanking and that most decisions 
failed to meet the criteria of an informed decision (Chapter 3).  The results of the non-
experimental, descriptive and correlational survey are presented in this paper.   
Participants  
 Five hundred surveys were mailed by the MDHHS to mothers who gave birth within the 
last three months in the state of Michigan. The initial sample was randomly selected by MDHHS  
using a random number generator.  The Newborn Screening Follow-up Program database by 
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MDHHS was used to select the sample.  The final study sample consisted of respondents to the 
survey.  Eligibility criteria for the quantitative portion of the study included the mother of the 
newborn in the household: 1) was ≥18 years of age and 2) had a newborn 0-3 months of age.  
Exclusion criteria included subjects with no BioTrust parental consent decision (yes or no) on 
file with MDHHS or evidence of an infant death in the state database.  
Data collection 
Five hundred survey packets were prepared, each containing: (a) an invitation letter, (b) 
an informed consent form, (c) a letter from MDHHS explaining the project (d) study instruments 
(i.e. Biobanking Attitudes and Knowledge Survey [BANKS] (Wells et al., 2014); 10-Item Hoge 
Intrinsic Religiosity Motivation Scale (Hoge, 1972); Short Schwarz’s Value Survey (Lindeman 
& Verkasalo, 2005), and a brief investigator developed demographic questionnaire (Appendices 
B-H).  The invitation letter and informed consent form described the research project.  A PI-
addressed stamped envelope was included for participants to return the materials within one 
month of receipt.  A two-dollar bill was also included in the packet as an honorarium to thank 
participants for their time and effort.  Survey packet envelopes were sealed and hand-delivered to 
MDHHS in Lansing, MI, whose staff then added the mailing address of potential participants. 
This was done to safeguard the protected health information (e.g. names, addresses) of potential 
participants. The study team was not aware of the names or mailing addresses of potential 
participants.   
A modified Dillman approach (Dillman, Smyth, & Christian, 2009) was used that 
included one initial mailing and one reminder postcard mailed seven days later.  Reminder 
postcards were mailed by MDHSS, to the same 500 potential participants, to thank those who 
completed the survey and to remind those who had not yet done so to complete and return the 
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survey.  Survey responses were completely anonymous, as no identifying links or codes were 
collected or maintained. The IRB granted a signature waiver on the consent form to maintain 
anonymity of the respondents.  Return of the completed survey was considered evidence of 
consent to participate.  
Measures  
 Measure of Informed Choice. Marteau et al. (2001) categorical rubric of knowledge, 
attitudes, and decisions was used to measure informed choices. This 8-cell typology classifies 
knowledge as good or poor and attitudes as positive or negative and examines the congruency of 
the health decision (yes or no) with attitudes.  The MMIC requires dichotomization of 
knowledge and attitude data from continuous scales using an absolute score, the sample mean, or 
the scale mid-point.  Choices are considered informed when individuals demonstrate good 
knowledge and positive attitudes that result in participation, and also when individuals 
demonstrate good knowledge and negative attitudes that result in a decision not to participate. 
All other possible combinations of knowledge (good/poor), attitudes (positive/negative), and 
decision (yes/no) are considered uninformed choices (Marteau et al., 2001).  The rubric was 
applied to the knowledge, attitude, and participation decision data to evaluate the proportion of 
informed choices among mothers regarding MI BioTrust donation decisions.   
 Standardized instruments.  Three standardized instruments with sound reliability and 
validity measures were used in this study (Table 11).  A description of each follows. 
Biobanking attitudes, knowledge, self-efficacy. The Biobanking Attitudes and 
Knowledge Survey (BANKS) tool includes three, self-contained, multiple-item scales to measure 
biobanking- related constructs: attitudes, knowledge, and self-efficacy (Wells et al., 2014). The 
attitude scale consists of 14 items using a 5-point Likert-type scale (Strongly Agree, Agree, 
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Neither Agree nor Disagree, Disagree, Strongly Disagree) to measure attitudes about 
biobanking. An example of a question is: “People who give biospecimens help prevent diseases”. 
Ratings are summed for a final attitude score. The scale includes both positively and negatively 
worded items. Positively worded items are reverse coded, as higher scores indicated more 
positive attitudes (Wells et al., 2014).  
 The knowledge scale consists of 16 items with categorical responses (yes, no, don’t 
know).  Many questions represent elements of informed consent for biobanking. For example, the 
item, “A person can stop being in a research study after giving a biospecimen”, reflects the 
element of informed consent concerning the right to withdraw from a study.  A knowledge score 
is obtained by counting the number of correct responses (raw score) and dividing the number of 
correct responses by the total number of items (% correct). “Don’t know” responses are counted 
as incorrect. A higher number/percentage of correct responses indicates more knowledge about 
biobanking.  
 The 12-item self-efficiency scale uses a horizontal, segmented, numeric rating scale (0 = 
Cannot Do to 10 = Highly Certain I Can Do) to determine a participants’ confidence in donating 
biospecimens under certain conditions.  For example, “I think I could give a biospecimen to a 
biobank even if it is against my religious beliefs”. Ratings are summed to create a self-efficacy 
score, with higher scores representing more confidence about donating biospecimens.  
 The remaining 3-single items in the BANKS tool ask about intentions to donate and 
receptivity to more information. As mothers had already made the decision about donation, these 
were not applicable to this study, and therefore were not included.  
 Influence of religious values on biobanking decisions. The Hoge Intrinsic Religiosity 
Motivation Scale (1972) was used to measure the influence of religious values on biobanking 
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decisions. It is a 10-item, 4 point Likert scale questionnaire that measures underlying religious 
motivations for behavior. Ratings are summed and averaged for a total intrinsic religiosity score. 
Negatively worded items are reversed scored so that a lower score is indicative of more intrinsic 
religious motivation (Hoge, 1972).    
 Personal Values.  The Short Schwartz’ Value Survey (SSVS) is a 10-item questionnaire 
that asks respondents to rate the importance of specific values as life-guiding principles using a 
Likert-like scale of 0-8 (0= opposed to my principles, 8= of supreme importance).  This 
shortened version of the Schwartz’s Value Survey (Schwartz 1992, 2012) was used to reduce 
participant burden, and has acceptable correlations values among similarly aged participants (e.g. 
college students) (correlations ranged from 0.45 to 0.70 across items; all p values < .001) 
(Lindeman & Verkasalo, 2005).  The SSVS was used as a measure of the personal values that 
may be motivating respondents.   
Ethical considerations  
Approval to conduct this study was obtained from the institutional review boards (IRBs) of the 
university and MDHHS.  
Data Analysis 
 Each returned survey was scored per the respective measurement tool instructions.  Data 
were entered, checked for accuracy, and analyzed using IBM SPSS Statistics for Windows, 
version 24 (IBM Corp., Armonk, N.Y., USA). First, descriptive statistics were used to analyze 
data from questions on the BANKS scales of knowledge, attitudes, and self-efficacy, the Hoge 
IRM scale, the SSVS and the demographic questionnaire.  Normality of these continuous 
variables (i.e. knowledge, attitudes, self-efficacy, and religiosity scores) was assessed by visual 
inspection of histograms and the Shapiro-Wilk test.  Attitude and religiosity scores differed 
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significantly from the normal distribution. Thus, t-tests were used to identify any significant 
differences between means for knowledge and self-efficacy scores and the Mann-Whitney U test 
was used to compare distributions of attitude and religiosity scores between mothers who agreed 
and those who declined. Chi Square tests were used to assess significant associations among 
categorical variables (e.g. demographics). Multivariate linear regression was conducted to 
identify significant factors contributing to increased knowledge.   
 The primary outcome variable was making an informed choice. The analysis of informed 
choice involved three variables (a) a decision (i.e. yes or no) about donating the rDBS (b) a 
knowledge scale score and (c) an attitude scale score. Only scales that were 100% complete were 
used in this analysis.  Therefore, most analyses were run on a subset of data which required that 
each respondent had: (a) remembered her decision about donating the bloodspots (i.e. yes or no) 
and (b) completed the knowledge and (c) completed the attitude scale.  A flow chart of survey 
respondents in the analysis of informed choices is presented (Figure 4). Next, knowledge and 
attitude scores were dichotomized to classify choices as informed or uninformed.  The scale mid-
point (i.e. 50%) for knowledge was used as the cutoff for adequate or inadequate knowledge and 
the mid-point of the attitude scale (range 14-70; mid-point 42) was used as the cut-off for 
positive or negative attitudes.  Attitudes were then compared to the biobanking decision of the 
respondent for value consistency; positive attitudes with a decision to donate and negative 
attitudes with a decision not to donate were labelled as value consistent.  Lastly, a forward 
logistic regression was performed to identify other factors such as age, education, parity, race, 
and religion that may have contributed to making an informed or uninformed choice.  Missing 
values were reported (and not included) as indicated; no data were imputed. All tests are two-
tailed, using p= < 0.05 to denote statistical significance.   
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Results 
 Of the 500 surveys, 16 were returned to MDHHS as undeliverable and 83 were returned 
to the PI, for an initial response rate of 17.2% (83/484).  However, three envelopes were returned 
without any responses, for a useable returned sample of 80.  Of these, 63 mothers (78.75%) 
reported having agreed to donate their newborn’s blood spots for research; 9 (11.25%) declined; 
8 (10.0%) did not recall their decision. The study sample mostly self-identified as of white race, 
with at least a high school education and between the ages of 26-45 years of age.  More than 
three-quarter of the respondents had private insurance.  The representation of primiparous and 
multiparous mothers in the study sample closely mirrored Michigan data (Table 12).   
  There were no significant differences in the demographic characteristics of mothers who 
agreed or declined to donate rDBS, likely due to the small number of decliners in the sample 
(n=9; 11.25%) (Table 13).  Because of the small number of decliners, logistic regression was not 
able to be conducted to analyze the outcome of agree or disagree, which would have required a 
larger sample size for robust results (Peduzzi, Concato,  Kemper, Holford, Feinstein, 1996).  No 
significant differences in mean scores were noted on the knowledge and intrinsic religiosity 
scales between mothers who agreed or declined to donate their newborn blood spots for research 
purposes.  However, there were significant differences in mean scores for attitudes (55 vs. 48, 
p=.036) and self-efficacy (72 vs. 40, p=.002), with decliners having lower scores (Table 14).  
Knowledge 
 Overall, knowledge scores were low with a mean of 47% (i.e. fewer than 8/16 questions 
answered correctly).  No significant difference was noted in the mean knowledge score between 
mothers who agreed or declined to donate (Table 14).  However, mean knowledge scores were 
significantly higher among the 71 mothers’ who remembered their donation decision (and 
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completed the knowledge scale; M= .49, SD.22) than among the seven mothers who did not 
remember their donation decisions (M=.22, SD.08) (degrees of freedom adjusted for unequal 
variances; t (17.25) = -6.91, p= <. 001, 95% confidence interval [-.36, -.19], d=.6).    
 Eighty percent of participants (n=64/78) correctly answered questions about not having to 
spend money to donate biospecimens and 82.5% (n=66) correctly answered the item that 
scientists must keep a person’s information private when doing research.  However, only 10% of 
the mothers’ (n=8) knew that profit can potentially result from donated biospecimens, 21% 
(n=17) correctly indicated they would not necessarily be contacted about the risk of a disease, 
and approximately 1 in 5 (n=17; 21.3%) knew they could withdraw from a study after donating a 
biospecimen (Table 15).  A backward elimination multiple regression revealed the two variables 
education (p=.002) and parity (p=.002) that best predicted knowledge scores (Table 16). 
Attitudes and Values  
 Attitude data (Table 17) from mothers who agreed and mothers who did not agree to 
donate did not meet the assumption of normality and homogeneity of variances (Table 14). As 
such, a Mann-Whitney U test comparing rank order was conducted.  Results indicated attitudes 
were significantly higher for mothers who agreed to donate blood spots compared to mothers 
who declined donation (U = 152.5, p=.036).   
Self-efficacy scores also varied significantly between mothers who agreed to donate 
blood spots and those who declined (Table 14).  Among participants who agreed to donate their 
newborn’s blood spots, self-efficacy ratings were lowest on the item related to donating 
biospecimens even if it was against religious beliefs (Table 18). No relationships were noted 
between identifying a religious affiliation, or intrinsic religiously scores and agreeing or 
declining to donate blood spots (X
2
= 0.571 (1) p=.708; X
2= 32.0 (34) p=.566, Fisher’s Exact test 
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p= .741) or between personal values on the SSVS between those who agreed or declined to 
donate blood spots (Figure 5; Table 19).  Achievement was rated as more important among those 
mothers who declined to donate their newborn’s rDBS than among mothers who agreed to 
donate their newborn’s rDBS (t (68) =1.996, p= .05, 95% confidence interval [.00, 2.2], d=.9 ; U 
= 160.0, p = .039). 
Informed Choice  
 Using the MMIC, 55% (38/69) of mothers made an informed choice about rDBS 
donation and 45% made an uninformed choice (31/69). Six decisions (8.7%) were not consistent 
with positive attitudes toward biobanking, such that attitudes were classified as positive yet 
resulted in the mother declining to donate blood spots.    
 To ascertain effects of demographic characteristics on making an informed choice a 
forward selection logistic regression was performed (Table 20).  Insurance status (a proxy for 
socioeconomic status) was not included due to the small sample size and collinearity with 
education (χ 2(1) = 24.514, p =< .001; r=.609, p= < .001).  Six insurance responses were missing 
and cross tabulation showed no one with ≤ high school education had private insurance (i.e. data 
separation). All variables included in the logistic regression were categorical. The final logistic 
regression was statistically significant, χ2 (2) = 15.886, p= < .001 and included parity and 
education (Table 9) as factors influencing an informed choice.  While statistically significant, (χ2 
(2) = 15.886, p= < .001) the model only explained 21-28% of the variance (Peng, Lee, & 
Ingersoll, 2002) and correctly classified 71.0% of cases.  Mothers with > high school education 
were 8.47 times (95% confidence interval [1.484, 48.302]) more likely to make an informed 
choice than those with ≤high school education.  Multiparous mothers were 5.35 times more 
109 
 
likely to make an informed choice than were primiparous mothers (95% confidence interval 
[1.786,16.027]) (Table 20).   
Discussion 
 This study provides a cross-sectional view of the biobanking knowledge, attitudes, and 
values of mothers who made a decision about donating their newborn’s blood spots for research. 
Low knowledge scores were associated with nearly half of the participants making uniformed 
decisions.  The knowledge scores are comparable to results from other studies on understanding 
informed consent for biobanking where low knowledge scores were found (Eisenhauer et al., 
2017; Falagas, Korbila, Giannopoulou, Kondilis, & Peppas, 2009), and to prenatal screening 
studies that used the MMIC and found low knowledge to be a factor in uninformed choices 
(Gourounti, & Sandall, 2008; Marteau et al. 2001; Piechan et al. 2016; van den Berg et al., 
2006).  Similarly, Lehmann, de Melker, Timmermans, & Mollema (2017) found low knowledge 
scores among parents of at least one child between 3 months and 3.5 years of age who decided 
not to vaccinate their children.  
 While there is no gold standard of a passing score or cut-off for good knowledge of 
informed consent information, ideally, the participant should know all of the information 
pertaining to the required elements of informed consent (e.g. risk and benefits). However, due in 
part to a lack of information provided and limitations in the cognitive abilities or in attention, this 
is rarely the case (Sand et al., 2010).  Nonetheless, participants should be able to demonstrate a 
good level of gist understanding, the understanding of risks and benefits of participation given 
one’s personal values in real-life contexts (Reyna, 2008). Moreover, a minimal passing score for 
knowledge tests is needed to compare scores across studies (Eisenhauer et al., 2017).  The field 
of education often uses an absolute score of 80% as passing on tests of mastery for subject-
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matter, appropriate to demonstrate competence for a particular purpose (Guskey & Anderman, 
2013; Norcini, 2003).   Using the same educational standard of 80% only five mothers (7%) 
would have been be classified as having made an informed choice in the current study. 
 It is also important that potential participants have prerequisite knowledge to make an 
informed choice because this is the threshold set for participation in clinical research by the 
Nuremberg Code and the Declaration of Helsinki (Trials of War Criminals, 1949; World Medical 
Association, 2013).  While setting a standard score always involves an element of judgement 
(Zieky, 2001), it reflects researchers’ values and represents the level of knowledge that is 
deemed important for participants to be well informed before agreeing to participate in 
biobanking research.  Low expectations of participant understanding may precipitate decisional 
regret (Wiggins, 2013). The BANKS knowledge test represents common elements of informed 
consent for biobanking, upon which experts have agreed are minimally required for participation 
(Beskow et al., 2015; Wells et al., 2014).  Indeed, when elements are considered essential, scores 
of 100% are expected (Beskow, Lin, Dombeck, Gao, & Weinfurt, 2017) potentially making a 
minimal expectation of 80% unacceptable.  Likewise, setting a passing rate for study participants 
(e.g. 80% of a sample answered the question correctly or passed the comprehension test) 
provides a similar benchmark that has been used in studies of informed consent (Falagas et al., 
2009).   
 Gaps have been identified in the information about biobanking presented to potential 
research participants and to the public via the media and frequently involve the lack of disclosure 
about controversial uses for rDBS and other biospecimens (Caulfield, 2005; Eisenhauer et al., 
2017; Ogbogu et al., 2014; Tomlinson et al., 2014).  The focus of biobanking information is 
often on possible benefits to society, with a lack of focus on personal risks (Caulfield, 2005; 
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Eisenhauer et al., 2017; Ogbogu et al., 2014; Tomlinson et al., 2014).  To be more balanced, 
information about biobanking should present both positive and potentially negative controversial 
outcomes.  Given the insights provided by this research, potential research uses for rDBS, 
including potential threats to personal or religious values (e.g. exposure of private genetic data, 
prenatal genetic testing, predicting the future), should be described.  
Limitations and Strengths 
 There were four primary limitations to this study: (1) a low response rate; (2) data 
obtained from only the state of Michigan, with a provision for opt-in consent; and (3) 
measurement limitations and (4) the use of categorical variables. The low response rate (17%) 
occurred despite sending a reminder postcard one week after the initial survey mailing and 
including a $2 honorarium.  Because of financial limitations, larger incentives and repeated 
mailings were not feasible.  Surveys were mailed to mothers who gave birth within the last 3 
months in order to minimize recall bias. However, as new mothers are often tired and stressed, 
this may also have contributed to the low response rate.  Moreover, only scales that were 100% 
complete were used in the analysis of informed choice further reducing the sample size.  The 
response rate, however, is not unlike that in similar studies.  Lehmann et al. (2017) for example, 
sent letters to 8000 parents inviting them to answer an online survey. Although these authors had 
a greater number of responses (1615 parents), their overall response rate was similar to that 
experienced in the current study (16.2%).  The response rate from mothers who declined to 
participate in the BioTrust was also small. This small sample may represent a response bias and 
because survey was anonymous, data on non-respondents was not able to be collected.  Further, 
the study sample was mostly White, and did not include responses from African Americans 
mothers.  African Americans frequently decline to participate in research based on fear and 
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distrust given the history of past research abuses (Shavers‐Hornaday, Lynch, Burmeister, & 
Torner, 1997). The sample was older, more educated, and somewhat less religious in comparison 
to state level data. Demographic differences may affect the generalizability of the data.  A larger 
sample size would have also allowed for the creation of a neutral attitude category that may have 
more accurately reflected values (van den Berg, Timmermans, ten Kate, van Vugt, & van der 
Wal, 2005).  While the results may not be generalizable the larger population, the findings 
provide insight on the knowledge, attitudes, and proportion of informed choices, especially 
among White mothers in Michigan who agreed to donate rDBS to the BioTrust.  Moreover, the 
similarity of parity between the study data and the Michigan population give credence to the 
observation that parity influences knowledge and informed choices, suggesting that experience in 
making this decision matters.   
 Second, surveys were only mailed to mothers in Michigan. Fathers were not included and 
may have had different responses if surveyed.  However, because Michigan is one of few states 
that offer an opt-in consent process for use of rDBS, this also a strength of the research, as it 
provides data on a unique situation.  
 Lastly, the MMIC required dichotomization of knowledge and attitude data and such 
classifications may have overlooked important gradations within the data (Dawson & Weiss, 
2012).  In an effort to make the demographic sheet easy for respondents to complete, check 
boxes were used and age was collected as a categorical variable which did not allow for analysis 
of it as continuous variable and, as such, differences may have been missed.  A noted limitation 
of a quantitative approach is that the reasons for donating or declining to donate rDBS are not 
always obtainable from the survey questions asked.  As such, a qualitative semi-structured 
interview study was also conducted and provides a source of rich detailed data for comparison 
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(Eisenhauer et al., 2018 unpublished data).   Furthermore, while the MMIC is a reliable and valid 
rubric for informed choice, it is limited to the categories of knowledge, attitudes, and the 
participation decision, it may not have adequately captured the complexities of an informed 
choice, involving components such as appreciation, deliberation, and reasoning (Appelbaum & 
Grisso, 2001; Lehmann et al., 2017; Roth et al., 1977; van den Berg, et al., 2006).  The use of 
standardized measures to assess biobanking knowledge, attitudes, self-efficacy, intrinsic 
religiosity, and personal values was an additional strength of the study as they make comparisons 
across studies more feasible, and have been under-utilized in studies on understanding informed 
consent for biobanking (Eisenhauer et al., 2017).  
Recommendations and Future Work 
 Findings from this study indicate that low biobanking knowledge scores, the importance 
of values in biobanking decisions, and education and experience (i.e. parity) of the participants 
contribute to making an informed choice about biobanking. Therefore, the following 
recommendations are put forth: 
1.  Education about NBS and research use of rDBS along with the consent request should be 
moved to the prenatal environment. This would provide parents more time to consider 
biobanking information, deliberate, and discuss their decision, which may aid in making 
informed choices, based on our data, especially, for first time mothers (American College of 
Obstetricians and Gynecologists, 2015; American Academy of Pediatrics, 2000, 2008; Botkin et 
al., 2016; van den Berg et al., 2006).  There are a host of distractions and other important 
decisions to make in the postpartum environment (Lowe, 2004; Torres & De Vries, 2009) that 
may impede informed consent for biobanking.  
114 
 
2. Evidence-based decision aids that include more balanced information and value-clarification 
exercises (Stacey et al., 2017) should be developed and certified  using International Patient 
Decision Aid standards (IPDAS, 2013), and evaluated by third parties, not invested in recruiting 
biobank participants, to help ensure that information provided is not biased.  Currently, consent 
forms, information brochures, and educational materials are written by MDHHS and may be 
biased in favor of biobanking because the state government has decided biobanking is a good 
investment in public health.   Implementing standardized tools designed to elicit and clarify 
values will help to provide appropriate, tailored information to each potential participant. 
Decision aids have been shown to be effective in improving informed choices other preference-
based healthcare decisions (Stacey et al., 2017). 
3. A standardized assessment of participant understanding needs to be implemented at each 
biobanking consent encounter.  While there are a plethora of instruments available to assess 
individual understanding, they are rarely used in clinical settings (Dunn, Nowrangi, Palmer, 
Jeste, & Saks, 2006).  If an instrument is not used, understanding may not be ensured.  
4. A standard passing score for knowledge tests needs to be agreed upon for studies of 
understanding informed consent in order to make accurate comparisons across studies.   While 
we used a passing score of 50% to classify informed choices for this study based on instrument 
scoring instructions, we also offered support from the literature for using 80% as the cut-off 
which would have dramatically reduced the proportion of informed choices.  
 Future work should include follow-up studies to examine the effects of content and 
context of biobanking education on informed choices.  Additional research on the role of values 
in decision-making about biobanking is also needed. Likewise, the credentials, education, and 
training of consenters need further study as the skills and perceptions of the person obtaining 
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consent influences biobanking decisions (Eisenhauer et al., 2017; Hoeyer, 2003). Valid and 
reliable instruments are needed to assess consenters’ skills, and the degree to which 
organizations, including state health departments, facilitate informed choices by structuring 
processes in a truly patient centered fashion (Rudd, 2014).  Finally, different analytic approaches 
of passing scores requires further psychometric testing, including exploring alternative scoring 
methods such as formula scoring (Nunnally & Bernstein, 1994), receiver operating characteristic 
curve analysis, sensitivity and specificity testing (see e.g. Jeste et al., 2007), and other techniques 
comparing test scores against the judgment of human experts such as the Angoff method (1971).  
While these techniques are beyond the scope of the current manuscript, they are essential for 
further research on creating a standard of study knowledge for informed consent.  
Conclusion 
 This study examined mothers’ of newborns level of biobanking knowledge, attitudes, and 
personal and religious values, and determined the proportion of informed choices using 
established standardized measures.  Findings indicated that knowledge scores were low, attitudes 
toward rDBS were positive, and just over half of the mothers’ decisions were classified as 
informed choices.  Given the widespread lack of knowledge, it is important to examine the 
process of biobanking education and make procedural changes to facilitate informed choice. 
Effective interventions such as transferring education about research on rDBS from the 
postpartum period to the prenatal period, and the use of decision aids that incorporate value- 
based information, must be developed and implemented.  
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Table 11. Psychometric characteristics of measures 
Citation Instrument Variables #/Items  Reliability & 
Validity  
Wells  
et al.,  
2014 
Biobanking attitudes 
and knowledge 
survey (BANKS) 
Biobanking  
Knowledge 
Attitudes 
Behavioral 
skills (Self-
Efficacy) 
45 items total 
(42 included) 
 (3 additional single-item 
measures not applicable 
to current study) 
Cronbach’s alpha 
Attitudes= 0.88 
Self-efficacy=0.95  
Hoge,  
1972 
Intrinsic Religious 
Motivation Scale 
Religious 
values  
10-items 
Intrinsic Religious 
Motivation Scale 
Kuder-Richardson 
formula 20 =0.901 
 
Lindeman & 
Verkasalo,  
2005 
Short Schwartz’s 
Value Survey – SSVS  
Personal values  10-items about personal 
values 
Intraclass 
correlations  
0.34-0.77  
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Table 12. Demographic Characteristics of All Survey Respondents (n=80) and Michigan Comparison Data 
Variable n (%)
 Michigan Comparison Data 
e
 
Donation Decision  Donation Decision  
    No 9 (11.3) No 19% 
    Yes 63 (78.8) Yes 66% 
    Don’t Remember 8 (10.0) No Signature 14% 
Age   Age  
     18-25 10 (12.5) 18-24    27.7% 
     26-45 70 (87.5) 25-40+ 70.6% 
Level of Education 
a
  Level of Education  
     4
th
-12 Grade  3 (3.8) <HS 11.7% 
 HS or GED 9 (11.3) HS Grad/GED 24.1% 
Some College or  Vocational School 11 (13.8)  Some College 33.5% 
     Associate’s Degree 11 (13.8)  College Degree + 30.7% 
     Bachelor’s Degree 32 (40.0)    
     Master’s Degree 8 (10.0)    
 PhD/ Professional    6 (7.5)   
Insurance Status 
c
  Insurance Status  
     Public  16 (20.0) Public  29.5% 
     Private 58 (72.5) Private 54.2% 
Religiously Affiliated 
d
  Religiously Affiliated  
     No 26 (32.5) No 24% 
     Yes 54 (67.5)  Yes 75% 
Race 
b
  Race  
     Asian 2 (2.5)  Asian 2.4% 
African American/ Black 2 (2.5) African American/Black 17.8% 
     Hispanic or Latino 5 (6.3) Hispanic or Latino 5.6% 
     White  69 (86.3)   White  70.2% 
     Other 2 (2.5) Other 3.9% 
Number of Births   
  
Primiparous 33 (41.3)  41.2% 
Multiparous 47 (58.8)   58.8% 
a, b 
Variables were collapsed for further analysis due to small cell counts (i.e. race: non-white or white; education: ≤ 
high school (HS) or  > HS). 
c
 insurance: proxy for socioeconomic status; n=74; three missing responses and 3 
responses of “both” (not included in analysis). d Identified religions: Catholic (n=16) or Protestant (n=31) Christians; 
Other (n=2); Not Specified (n=5). Total percentages may not equal 100 due to rounding. 
e Michigan Comparison 
Data sources: MDHHS, 2016 as cited by Rothwell et al., 2017 ; Haak, Paciorek,,Sauter, (2017). Michigan PRAMS 
Data Tables 2014; Pew Research Center: Religion & Public Life. (2017). Religious Landscape Study: Adults in 
Michigan. Retrieved from http://www.pewforum.org/religious-landscape-study/state/michigan/# 
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Table 13. Demographics and decisions to donate blood spots (n=72) 
Variable Agreed 
n=63 n (%) 
Declined 
n=9 n (%) 
Test* 
Age     
     18-25 10 (15.9) 0 (0)  
     26-45 53 (84.1) 9 (100.0) p=.343 
Level of Education      
      ≤HS 11 (15.3) 0 (0)  
 >HS 52 (84.7) 9 (100.0)  p=.337 
Insurance Status (n=66) 
c
    
     Public  12 (21.1) 2 (22.2)  
     Private 45 (78.9) 7 (77.8) p=1.0 
Religious Affiliation 
d
    
     No 22 (34.9)  2 (22.2)  
     Yes 41 (65.1) 7 (77.8) p=.708 
Race 
b
    
     White (only) 54 (85.7) 8(88.9)  
Other 9 (14.3) 1(11.1) p=1.0 
Number of Births (includes 
current birth) 
   
Primiparous 27 (42.9) 2 (22.2)  
Multiparous 36 (57.1) 7 (78.8) p=.297 
*All 2x2 chi squared tests p values are based on Fisher’s Exact test due to some cells with counts < 5. 
c
Insurance status: proxy for socioeconomic status; n=66 (8.3% missing data): 3 missing responses and 3 
responses of “both” not included in analysis. 
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Table 14. Mean differences in continuous scored variables according to mothers’ decision to donate blood spots 
Variable 
 
Overall 
(N=80) 
 
Shapiro
-Wilk Donation Decision Test 
95% Confidence 
Interval of the 
Difference 
     Agreed (N=63) Declined (N=9)     
 n Mean SD Sig. n Mean SD n Mean SD t df 
Sig. 
(2-
tailed) Lower Upper 
BK % 78 0.47 0.22 .068 62 0.49 0.22 9 0.49 0.19 -0.061 69 .951 -0.16 0.15 
BK # 
correct 78 7.45 3.56 .067 62 7.85 3.55 9 7.78 3.07 -0.062 69 .951 -2.57 2.41 
*BA 
score 75 53.83 7.36 .012 60 55.13 5.92 9 47.67 10.95 -2.002 8.71  .077* -15.95 1.02 
BSE 
score 74 67.31 30.41 .132 58 72.00 26.93 9 39.56 33.53 -3.254 65 .002 -52.36 -12.53 
**HIR 
score 72 2.85 1.17 .007 56 2.93 1.191 8 2.40 1.36 -1.158 62 .251 -1.45 0.39 
Note: BK=BANKS Knowledge scale; potential range 0-100% or 0-16 correct questions. BA=BANKS attitude scale; potential range 14-70; higher 
score =more positive attitude toward biobanking. BSE= BANKS Self-efficacy scale potential range 0-100 higher score=more self-efficacy in 
donating biospecimens. HIR= Hoge (1972) intrinsic religiosity scale; potential range 1-5; lower score =more intrinsic religiosity. * Banks Attitude 
score is ordinal, Likert scale data. Levene's Test for Equality of Variances: F=7.679 p=.007, thus table reports equal variances not assumed; if 
assumed: t (67) = -3.109, p=.003, 95% confidence interval [-12.261, -2.673]; Mann Whitney U test for ranks significant for attitudes:  U = 152.5, p 
= .036. **Mann Whitney U test not significant for HIR: U=165.00 p=.231. 
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Table 15. BANKS (Wells et al. 2014), knowledge scores by item. 
Note: Correct answers in Bold font 
  
BANKS-knowledge scale (N=78) Mean 46.5%  SD  0.22 Range 0-94% 
Item Yes, n 
(%) 
 
No, n 
(%) 
Do not 
know, 
n (%) 
Missing  
n (%) 
1. A person has to spend money to give a biospecimen  2 (2.5) 64 
(80.0) 
14 
(17.5) 
0 (0.0) 
2. Anyone can access the biospecimens people give 1 (1.3) 52 
(65.0) 
27 
(33.8) 
0 (0.0) 
3. Research results from biospecimens will show up in 
medical records 
4 (5.0) 39 
(48.8) 
37 
(46.3) 
0 (0.0) 
4. Biospecimens given to a biobank will be sold to drug 
companies 
5 (6.3) 22 
(27.5) 
53 
(66.3) 
0 (0.0) 
5. A scientist must keep a person’s information private when 
doing research 
66 
(82.5) 
0 (0.0) 14 
(17.5) 
0 (0.0) 
6. The biospecimens people give can be sent to any 
organization that requests them 
13 
(16.3) 
34 
(42.5) 
33 
(41.3) 
0 (0.0) 
7. Police departments can legally get the biospecimens a 
person gives 
10 
(12.5) 
25 
(31.3) 
45 
(56.3) 
0 (0.0) 
8. Biospecimens given to a biobank can be sold to anyone 4 (5.0) 49 
(61.3) 
27 
(33.8) 
0 (0.0) 
9. Insurance companies can legally get the biospecimens a 
person gives 
1 (1.3) 41 
(51.3) 
38 
(47.5) 
0 (0.0) 
10. Researchers will always contact people if their 
biospecimens show risk for a disease 
17 
(21.3) 
17 
(21.3) 
46 
(57.5) 
0 (0.0) 
11. A person’s family can get information about the 
biospecimens a person gives 
5 (6.3) 34 
(42.5) 
41 
(51.3) 
0 (0.0) 
12. People can make money from donated biospecimens 8 (10.0) 33 
(41.3) 
39 
(48.8) 
0 (0.0) 
13. People no longer own their biospecimens after they give 
them to a biobank 
31 
(38.8) 
7 (8.8) 42 
(52.5) 
0 (0.0) 
14. After a person gives a biospecimen to a biobank, she/he 
can get it back 
5 (6.3) 39 
(48.8) 
36 
(45.0) 
0 (0.0) 
15. A person might be cloned if he/she donates a 
biospecimen to a biobank 
2 (2.5) 52 
(65.0) 
25 
(31.3) 
1 (1.3) 
16. A person can stop being in a research study after giving a 
biospecimen 
17 
(21.3) 
18 
(22.5) 
44(55.0) 1 (1.3) 
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Table 16. Multiple linear regression model of on outcome of biobanking knowledge scores
a
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
Collinearity 
Statistics 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound Tolerance VIF 
 (Constant) .226 .065  3.465 .001 .096 .357   
Education .205 .063 .344 3.239 .002 .079 .331 .998 1.002 
Parity .153 .047 .350 3.292 .002 .060 .246 .998 1.002 
a Non-significant variables included age, race, and religion. Model fit: F(2, 68) = 10.262, p= < 
.001, R=.481, R2 = .232, Adjusted R 2=.209 
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Table 17. BANKS (Wells et al., 2014) attitude results by item. (Most frequent response in bold) 
 
  
BANKS-Attitude scale (N=75) Mean 53.8  SD  7.4 Range 31-70 
Item Strongly 
Agree  
n (%) 
 
Agree  
 n (%) 
Neither 
Agree nor 
Disagree  
n (%) 
Disagree 
n (%) 
Strongly 
Disagree 
n (%) 
Missing  
n (%) 
1.  Giving a biospecimen is for 
the greater good of society 
29 (36.3) 30 (37.5) 18 (22.5) 2 (2.5) 0 (0.0) 1 (1.3) 
2.  People who give 
biospecimens help prevent 
diseases 
25 (31.3) 41 (51.3) 12 (15.0) 1 (1.3) 0 (0.0) 1 (1.3) 
3.  People who give 
biospecimens help cure diseases 
23 (28.8) 36 (45.0) 19 (23.8) 2 (2.5) 0 (0.0) 0 (0.0) 
4.  Giving a biospecimen is a 
waste of a person’s time 
1 (1.3) 1 (1.3) 6 (7.5) 40 (50.0) 32 (40.0) 0 (0.0) 
5.  Giving a  biospecimen will 
help future generations 
29 (36.3) 41 (51.3) 9 (11.3) 0 (0.0) 1 (1.3) 0 (0.0) 
6.  Giving a  biospecimen gets in 
the way of a person’s medical 
care 
5 (6.3) 0 (0.0) 10 (12.5) 28 (35.0) 37 (46.3) 0 (0.0) 
7.  Giving a biospecimen will 
help a person’s family 
11 (13.8) 34 (42.5) 30 (37.5) 5 (6.3) 0 (0.0) 0 (0.0) 
8.  Medical information is 
unlikely to be stolen from a 
biobank 
7 (8.8) 33 (41.3) 26 (32.5) 7 (8.8) 5 (6.3) 2 (2.5) 
9.  Giving blood to a biobank is a 
good way to help cancer 
research 
18 (22.5) 53 (65.0) 8 (10.0) 2 (2.5) 0 (0.0) 0 (0.0) 
10.  Personal information is 
unlikely to be stolen from a 
biobank 
9 (11.3) 35 (43.8) 24 (30.0) 6 (7.5) 6 (7.5) 0 (0.0) 
11. A person’s family medical 
information is safe in a biobank 
8 (10.0) 38 (47.5) 27 (33.8) 6 (7.5) 1 (1.3) 0 (0.0) 
12.  Biospecimens that people 
donate might be used for 
purposes they do not want 
7 (8.8) 18 (22.5) 28 (35.0) 22 (27.5) 4 (5.0) 1 (1.3) 
13.  A person should not donate 
biospecimens because it may 
identify health problems 
0 (0.0) 2 (2.5) 7 (8.8) 44 (55.0) 25 (31.3) 2 (2.5) 
14.  Giving biospecimens to a 
biobank may lead to more 
health care costs 
3 (3.8) 4 (5.0) 20 (25.0) 40 (50.0) 11 (13.8) 0 (0.0) 
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Table 18. BANKS (Wells et al., 2014) self-efficacy results related to values according to mothers decision to donate blood spots 
 Question Agreed  Declined              Test                         95% CI 
 n
1
 Mean SD n Mean SD t (df) p LL UL d 
 6. I think I could give a 
biospecimen to a 
biobank even if it is 
against my cultural 
beliefs 
63 4.95 3.37 9 1.22 3.31 
-3.11 
(70) 
.003 -6.12 -1.34 2.04 
 8. I think I could give a 
biospecimen to a 
biobank even if I am 
worried about how it 
will be used 
62 4.74 2.98 9 1.22 1.99 
-3.43 
(69) 
.001 -5.57 -1.47 2.08 
 11. I think I could give 
a biospecimen to a 
biobank even if it is 
against my religious 
beliefs 
62 4.10 3.39 9 1.33 3.32 
-2.29 
(69) 
.025 -5.17 -.360 1.5 
BANKS self-efficacy scale ranges from 0 (low self-efficacy) to 10 (high self-efficacy). Data drawn from 
subset of mothers who recalled their donation decision (n=72). 1n varies due to missing responses. 
SD=Standard Deviation. CI=Confidence Interval. LL=Lower Limit, UL= Upper Limit. Levine tests for 
homogeneity of the variance were non-significant; accordingly, table reports p values for equal 
variances assumed.  Because data for each question failed to meet assumption of normality, non-
parametric test (Mann Whitney U) was also conducted: question 6: U=97.5, p=.001; question 8: U=88.0, 
p=.001; question 11: U=126.0, p=.007. 
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Table 19. Ratings of personal values using The Short Schwartz Value Survey [SSVS] (Lindeman & Verkasalo, 2005) 
 Declined 
Mean 
(n=9) 
SD Agreed 
Mean 
(n=62) 
SD t-test 
Power 3.33 1.225 3.53 1.576 t=-.362(69) p=.718 
Achievement* 6.44 1.13 5.34* 1.59 t=1.996 (68) p=.050 
Hedonism 4.89 2.522 4.13 2.012 t= 1.025(69) p=.309  
Stimulation 5.11 1.764 4.31 1.896 t=1.199(69) p=.234 
Self-Direction 6.56 0.882 5.97 1.679 t=1.026 (69) p=.309 
Universalism 6.56 1.236 5.56 2.046 t=1.411(69) p=.163 
Benevolence 7.78 0.441 6.98 1.732 t=1.361(69)p= .178 
Tradition 6.11 2.522 5.66 1.708 t=.693 (69) p= .491  
Conformity  5.78 2.279 5.21 2.136 t= .740 (69)p= .462 
Security 6.00 2.179 5.69 1.77 t=.471 (69)p=.639 
SD=Std. Deviation * 61 valid responses for Agreed and Achievement, p=0.05. 
Total n= 71/72 mothers who remembered donation decision (yes/no) and completed the Short Schwartz 
Value Survey (one person left entire scale blank). 
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Table 20. Final forward logistic regression model of age, education, number of births, race, and religion on outcome of informed 
choicea 
Variables
b
 B S.E. Wald df p 
Odds 
Ratio 
(OR) 
95% C.I. for OR 
Lower Upper 
 Education 2.136 .888 5.781 1 .016 8.467 1.484 48.302 
Parity 1.677 .560 8.978 1 .003 5.351 1.786 16.027 
Constant -2.588 .941 7.564 1 .006 .075   
a
Not significant/Not included in model: age (0=18-25; 1=26-45) religion (0=no affiliation; 1=identified affiliation), 
race (0= non-White; 1=White). 
bEducation (0= ≤high school; 1=>high school), Parity 0= primiparous; 1= 
multiparous. 
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Figure 4. Flow chart of survey respondents and subset of data for analysis of informed choice (based on Moher et al., 2010) 
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Figure 5. Ratings of SSVS (Lindeman & Verkasalo, 2005) personal values between mothers who agreed and declined 
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Chapter 5 Discussion 
 
 This dissertation examined the understanding of information presented to mothers who 
made a decision about donating their newborn’s rDBS for research and the influence of 
knowledge, attitudes, and values on making an informed decision about participation in 
biobanking. The study designs used in Chapters 3 and 4 built on recommendations from the 
literature review that studies on understanding informed consent a) be conducted by non-biobank 
associated researchers, b) examine actual choices in real-time, c) use standardized instruments, 
and d) establish a threshold for defining adequate understanding and informed choice. 
Current Federal Policy  
 In 2011 the Secretary of Health and Human Services’ Advisory Committee on Heritable 
Disorders in Newborns and Children (SACHDNC) reviewed issues involving the use of rDBS 
and aimed to lay the foundation for national guidelines (Therrell et al., 2011).  Policy 
recommendations have fallen short (Tarini, 2011) and have not yet adequately addressed the 
issue. Arguably, the quandaries have only increased since the SACHDNC recommendations. To 
date, state laws about the storage and parental consent for research use of rDBS, remain 
inadequate, fragmented, and confusing (Genetic Alliance, 2018; Lewis, Goldenberg, Anderson, 
Rothwell, & Botkin, 2011).  Furthermore, federal legislation, The Newborn Screening Saves 
Lives Reauthorization Act of 2014, required parental consent for federally funded research with 
newborn rDBS and prohibited IRBs from waiving consent. However, the protections under this 
law will no longer be effective if recent changes to the Common Rule are implemented as 
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planned (Federal Policy for the Protection of Human Subjects, 2017, 2018). With 4 million 
American newborns having blood spots collected each year, this as an important issue to address. 
Policy Implications and Recommendations  
 If changes in the federal laws reverse previous policy protections, parents may lose trust 
in the research enterprise, and this may also potentially jeopardize trust in related the newborn 
screening process (Institute of Medicine Roundtable on Translating Genomic-Based Research for 
Health, 2010). Parental concerns regarding rDBS being collected, stored, and distributed for 
research have already resulted in litigation in Minnesota and Texas (Carmichael, 2011) and more 
recently in Indiana (Stafford, 2017) and Michigan (Reynolds, 2018).    
 This dissertation research provides evidence that the current consent process is 
inadequate, as it does not always facilitate making informed decisions about donating rDBS for 
research. Yet, it is known that parents want to be asked permission before their newborns’ rDBS 
are used for research (Tarini et al., 2009).  Therefore, a meaningful consent process that 
facilitates informed decision-making must be developed that takes into account participants’ 
knowledge, attitudes, values, and the context of decision-making.  Findings from this research 
support the need to enhance the type, depth and clarity of information provided to participants, 
the process of consent and context in which the consent occurs, as well as, the training of the 
consenter.  As such, three specific recommendations are put forth: a) biobanking educational 
materials need to be more comprehensive, tailored to individuals’ needs and values, and include 
the ethical implications of the research; b) consenters’ knowledge about rDBS research and their 
communication skills for conducting informed consent processes must be enhanced, and c) the 
educational content about rDBS research should be moved from the postpartum unit into the 
prenatal setting. Each recommendation is discussed further below.  
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Recommendation: Tailored Biobanking Educational Materials 
 An overarching finding from this dissertation research was lack of knowledge and 
understanding about biobanking among many of the participants. The systematic review of the 
literature examining participants’ understanding of informed consent for biobanking revealed 
that elements of informed consent, especially those unique to biobanking (e.g., the genetic nature 
of the research, storage of DNA, and the risks associated with such research) were often poorly 
understood.   These findings are consistent with research examining understanding of informed 
consent for traditional clinical trials and treatments that have shown many participants have 
difficulty understanding consent information (Cohn & Larson, 2007; Falagas et al., 2009; Flory 
& Emanuel, 2004; Nishimura et al., 2013).  Because attitudes, beliefs, and values interact with 
knowledge (Rokeach, 1979) and participant knowledge about biobanking was poor overall, the 
full extent of the influence from values remains unclear.  Inasmuch as value-based information is 
not often provided to or discussed with individuals considering biobanking (Eisenhauer et al., 
2017), some individuals may not make important associations between research uses for 
biospecimens and personal values (Tomlinson et al., 2015), consistent with qualitative findings 
from this dissertation research.  
 Likewise, knowledge of the Michigan BioTrust for Health and biobanking was poor 
among many the participants in the qualitative and quantitative components of this dissertation 
research study.  When mothers were asked in semi-structured interviews to describe the 
Michigan BioTrust the majority indicated they did not know anything about it.  Similar responses 
were noted when asked to describe biobanking.  Lack of knowledge was also exhibited in the 
form of misunderstandings about the credentials of the consenter, the identifiability of the 
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biospecimens, the entity conducting the research, and the need for an additional heel stick for the 
biospecimen.   
 Gaps in information provided to mothers’ were noted.  First, while the blood spot card 
was created by MDHHS in collaboration with the Office of Human Research Protections 
(OHRP) and reportedly contains all eight required elements of informed consent (Rothwell et al., 
2017), it did not include value-based guidelines or ethical comparisons for types of research to be 
conducted or laboratory methods used, even though comparisons and value-based information 
are relevant to understanding (Brehaut, 2012; Tomlinson et al., 2014; 2015).   Definitions and 
explanations of key terms were also absent (e.g. DNA, low risk).  Further the distinction between 
newborn screening and experimental blood spot research was not made clear.  A recent focus 
group study (N=69) spanning three states indicated individuals found information on the blood 
spot card confusing (Rothwell et al., 2017).  While these elements are further explained in the 
MDHHS brochure, several mothers in this dissertation study reported not having read it.  During 
the observations of the consent process, the brochure was not observed being used by the 
consenter in the discussion with the mothers.  
 No information on potentially controversial research was observed being provided to 
individuals at the time of decision-making.  This gap in the process is consistent with studies of 
informed consent that do not report disclosing controversial ethical information to potential 
participants, and therefore, do not assess understanding of it (Eisenhauer et al., 2017).  If 
individuals are given clear examples of both non-controversial (e.g. advancing cancer treatment) 
and controversial research (e.g. substance abuse surveillance, advancing prenatal genetic testing), 
it may be found that biobanking decisions will be more congruent with personal values, and 
therefore decisions are more informed.  In turn, there may be less decisional regret and moral 
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distress, increased trust in research, and the information disclosed would convey a respect for 
human dignity, by providing information to allow each individual to make an informed decision.  
Knowing this will guide the development of interventions to improve understanding, facilitate 
informed choices, uphold values, and preserve the public’s trust.  A recent study by Tomlinson et 
al., (2015) showed that when U.S. adults (aged ≥18 years) were first asked if they would donate 
biospecimens to a hypothetical biobank and permit the biobank to “use [their biospecimens] for 
any research study that it allows, without further consent” (p. 417); 68% of individuals agreed.  
However, when they were given explicit examples about  biospecimen use for abortion research, 
patents and profits, and genetic links to violence, significantly fewer individuals were willing to 
donate (49.5 %, 55.2%, 58.1% respectively, p=. <001), indicating this information was important 
for many individuals and influenced their decisions.  Decisions may be made differently in 
different contexts; based solely on knowledge or attitudes alone, or by a complex combination of 
both; value tradeoffs may be necessary (Graham & Wiener, 1995).  However, even if ethical 
information does not determine the participation decision, it may be germane to informed 
decision-making for a substantial number of individuals (Tomlinson et al., 2014, 2015).   
 Tailoring information refers to delivering specific information to each person, based on 
his or her unique characteristics (e.g. age, cognitive capacity, educational level, religion, values) 
related to the outcome of interest, and derived from an individual level assessment (Kreuter & 
Skinner, 2000) and may help to increase informed decision-making. Li et al. (2016) 
demonstrated that values, beliefs, context, and personality influenced the types and amounts of 
information parents need to make informed decision about genetic sequencing for their children. 
One way to tailor informed consent information to the values and needs of individuals is through 
the use of evidence based decision aids (Stacey et al., 2017).  Decision aids, based on 
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standardized criteria, emphasize the importance of patient values in making health related 
decision.  Paradoxically, implementing such a standardized decision aid may facilitate the 
provision of tailored information based on what is meaningful to the patient via the use of an 
explicit value-elicitation and clarification process, and result in personalized recommendations 
based on expressed preferences (Stacey et al., 2017).   
 Evidence-based decision-aids for donation of rDBS and other biobanking research need 
to be developed, endorsed, tested and nationally standardized. Currently, consent forms and 
information brochures are written by MDHHS and may be biased in favor of biobanking because 
the state government has deemed this is a good investment in public health.  To help ensure that 
information provided is accurate, objective and unbiased, decision aids should be developed 
using International Patient Decision Aid Standards (IPDAS, 2013) and evaluated by third parties, 
who are not involved with recruiting potential biobank participants. Evidence-based decision-
aids have been shown to be effective in improving the quality of other preference-based 
healthcare decisions (Stacey et al., 2017).  While decision aids (Stacey et al., 2017) and other 
multimedia (e.g. DVDs, computer modules; Henry et al., 2009) may help deliver personal and 
relevant biobanking information, multimedia aids should only be used as an adjunct to personal 
communication, as extended discussion with a knowledgeable person has been found to be the 
most efficacious intervention to aid understanding of consent information (Flory & Emanuel, 
2004; Nishimura et al., 2013).   
 The overall results regarding biobanking knowledge indicate additional education about 
genetics, genomics, and biobanking is necessary for parents and consenters.  However, while 
knowledge is an important prerequisite for understanding, increasing individual knowledge alone 
may not increase the proportion of individuals making informed decisions. Increasing individual 
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level knowledge via traditional patient education is only one piece of current health literacy 
recommendations (Rudd, 2014).   
Recommendation: Enhanced Consenter Training 
 Education, training, and communication skills of the consenter are crucial elements of the 
consent process (Cohn et al., 2011).  The consenter observed in this research possessed 
misunderstandings. For example, the consenter used the word anonymous to describe blood spot 
research.  Blood spots are de-identified and coded when distributed to researchers, but can be 
identified by MDHHS, and therefore are not anonymous, thereby indicating a need for additional 
training.  
 While the MDHHS does provide periodic training to personnel at birth hospitals (Langbo 
et al., 2013; including at the hospital where consent was observed), the extent and frequency of 
this training is unknown. Educational efforts have evolved to include an online module with an 
optional certificate of completion (MDHHS, 2016), however it remains unclear whether these 
trainings are required, how compliance is monitored, how evaluation of consenters’ skills is 
conducted, or if there are minimum educational requirements for consenters.  The consenter in 
this study was a member of the ancillary nursing support staff. The job posting indicates the 
minimum requirement for this role is a high school diploma with an associate’s degree preferred.  
Formal human subjects’ training, such as that provided by the National Institutes of Health (NIH, 
2016) should certainly be required before any healthcare personnel conduct an informed consent 
process, and updated annually.  However, beyond the basic ethical principles of informed 
consent, consenters need on-going training and up-to-date knowledge of biobanking and rDBS 
research. In addition, the delivery of consent information requires assessment skills, advanced 
communication skills, provisions of comparisons, and value-clarification techniques (Brehaut et 
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al., 2012). Therefore, content of training for consenters needs to include information about the 
nuanced complexities of genetics and genomic science and not only general elements of 
informed consent, but those ethical, legal, and social issues unique to biobanking and rDBS 
research including (e.g. the return of results, the difference between newborn screening results 
and research results, coded versus anonymous research, genetic privacy and moral risks). 
Consenters’ knowledge in these areas should be tested and competency demonstrated before 
conducting consent for rDBS research with patients.  
 Consenters need also need communication skills including decision support skills and 
values clarification techniques; they need to be able to engage the potential participant in 
dialogue, help them ask questions, answer their questions, and provide empathetic and non-
judgmental support, and respect for a diversity of values and beliefs. These skills need to be 
practiced in role-playing scenarios and simulation activities in order to be well developed.  The 
informational brochure may need to be read aloud to the potential participant to ensure adequate 
information is provided and discussed.   The Ottawa Decision Support Tutorial (O’Connor, 
Stacey, & Boland, 2015) has been used as a guide in shared decision-making for patients’ 
making decisions about genomic sequencing for their children (Li et al., 2016).  The guide was 
designed to be used in skill-building workshops to improve healthcare providers’ knowledge of 
decision support and shared decision-making techniques including provider communication and 
value clarification techniques (O’Connor et al., 2015). This guide may be a useful tool in training 
consenter for rDBS research. However, many licensed health-care providers lack knowledge of 
and confidence in communicating genetic information (Guttmacher, Porteous, & McInerney, 
2007). Thus, expecting unlicensed personnel to conduct meaningful informed consent processes 
for complex genetic and genomic research including rDBS research without additional focused 
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training in the aforementioned areas may be unrealistic. If the consenter is not adequately 
informed, this person will be poorly equipped to answer questions and engage in knowledge 
based discussions with potential participants. 
Recommendation: Employing Nurses as Consenters 
 While the consenter in the qualitative study was not a nurse and did not introduce herself 
as a nurse, the credentials (or the perception of credentials), communication skills, and actions of 
the consenter may have influenced understanding and decision-making about biobanking 
research participation (Eisenhauer et al., 2017).  Further, because of the high degree of public 
trust in nurses (Norman, 2016), perceiving the consenter to be a nurse may have influenced 
mothers’ decisions to donate their newborn’s rDBS for research purposes (Hoeyer, 2003).  While 
trust in the consenter or institution conducting the research may motivate an individual to 
participate in biobanking, trust should not be conflated with objective understanding of 
information (e.g. risks and benefits) (Fisher & Fisher, 2000).   
 Because of their special preparation and knowledge nurses are in a position to assume 
roles in which they conduct the consent process (Hastings et al. 2012).  However, some nurses 
may also lack adequate knowledge and understanding of biobanking, genetics and genomics and 
the ethical implications involved (Badzek, Henaghan, Turner & Monsen, 2013; Sanner, Yu, 
Udtha, & Williams, 2013). As the field of genetics and genomics continues to grow, nurses are 
obtaining more education on these issues through nursing schools, continuing education, and 
other national opportunities (e.g., Summer Genetics Institute (SGI) sponsored by the National 
Institute of Nursing Research [NINR, 2017]). Biobanking and genetic research is an important 
area of science where nursing can and should lead as patient advocates. This needs to occur at 
the individual, organizational, and governmental policy level (Badzek et al., 2013).   
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 There are several reasons to promote nurses to act as consenters. Nurses are educated in 
therapeutic communication techniques, know how to assess patients’ values, attitudes and 
understanding, and advocate for patients prior to health related decisions (Bu & Jezewski, 2007). 
While it may be difficult to ensure decisions are not based on trust alone, asking potential study 
participants to articulate their reasons for participation can help clarify motivations and patient 
needs (Penckofer, Byrn, Mumby, & Ferrans, 2011).  Tools developed by nurses to assist in 
providing clear communication and adequate information should be used in the informed consent 
process (Cohn et al., 2011).  To advocate for consumers, in 2018 the American Academy of 
Nursing issued a policy brief calling for an increase in government oversight of private profit 
companies that offer direct-to consumer (DTC) genetic testing (Starkweather et al., 2018). In 
addition, the American Academy of Nursing warned of exploitation of consumers by these 
companies due to use of uncertified laboratories, lack of appropriate information about the 
meaning of test results, and the risk of genetic privacy violations and discrimination because 
DTC companies may sell consumers’ genetic data (Starkweather et al., 2018).  
Process 
 A very brief consent process was observed for the donation of rDBS to the BioTrust; 
limited information was provided and decisions were rendered quickly, often without much 
deliberation.  This likely contributed to several misunderstandings including who was conducting 
the research and the level of identifiability of the rDBS. Importantly, it was the MDHHS asking 
to collect, store, and distribute the rDBS for research, not the hospital or the university.  Mothers 
may have had different levels of trust for the MDHHS than for the hospital or its associated 
university. Moreover, informed decisions are not made solely based on trust, but rather with 
adequate knowledge and consistent with personal values (Marteau et al., 2001).  In addition, 
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because rDBS are de-identified and coded (MDHHS, 2015), they do not meet the standard 
definitions of anonymous biospecimens: “never labeled with personal identifiers when originally 
collected, neither is a coding key generated” (Food and Drug Administration, 2008, p.6).  As 
such, mothers who expressed a willingness to donate newborn’s rDBS based on the perception of 
anonymity may not have been fully aware of the implications of their decision. Different 
perceptions and information about the degree of identifiability of biospecimens are known to 
affect donation decisions (Hull et al., 2008; Robinson, Slashinski, Wang, Hilsenbeck, & 
McGuire, 2013). 
  To this end and to uphold the principle of veracity, it is imperative that this information 
be stated clearly and that accurate participant understanding be confirmed by the consenter 
through a validated comprehension check methods such as teach- back (i.e., the participant 
repeats back key information in their own words; Rudd, 2014).  The National Quality Forum 
recommends the use of teach-back as a standard element of the informed consent process 
(National Quality Forum, 2005).  Importantly, teach-back should be not an ad hoc practice, but 
rather endorsed by the institution as a standard practice and documented. Participants may need 
clarifications on some points and the teach-back process can be repeated two or three times until 
understanding is evident. If, however, understanding cannot be achieved after couple of 
iterations the participant should not be consent to the research study.  In addition, there are a 
plethora of other instruments available to assess individual understanding; often they are used for 
research on understanding and rarely used in clinical settings (Dunn, Nowrangi, Palmer, Jeste, & 
Saks, 2006). While some clinicians may believe such tools are too time consuming for clinical 
practice, several actually only take a few minutes to complete (Dunn, et al., 2006; Jeste et al., 
2007).  Other tools to facilitate the informed consent process include standard communication 
 146 
 
checklists; components of the communication process such as value clarification and teach-back 
are listed on a standard form to ensure they are incorporated into the process, but the content of 
communication is expected to be tailored to individual participants’ needs (Ripley, Tiffany, 
Lehmann, & Silverman, 2015). These instruments and tools could be adapted for use in the 
consent process for rDBS research and for other biobanking activities.   
Context 
 The context of the post-partum environment also influenced information use and 
decision-making by participants in this study. Mothers in the post-partum unit described being 
sleep-deprived, fatigued, under the effect of medication or in pain, and were observed to be 
preoccupied with their newborn during the consent process. There are numerous decisions that 
need to be made during the post-partum period, including decisions about newborn care, pain 
medication, breastfeeding, and male circumcision (Torres & De Vries, 2009).  Routinization of 
consent for such decisions may impede informed consent (Lowe, 2004; Press & Browner, 1997), 
making the process superficial.  Patients’ values and ethical dilemmas are often overlooked 
during consent for these procedures and the potential emotional consequences of the decisions 
are often not always fully explained (Lowe, 2004; Press & Browner, 1997).  It appears the same 
may hold true for the BioTrust decision, in this often physically and emotionally overwhelming 
context, where values and long-term implications of biobanking were not observed to be 
discussed during the observations of the consent process of this dissertation research. Findings 
from this study suggest that the postpartum environment is not the opportune time or context for 
this important decision. 
 In addition, the post-partum environment may mitigate the perception of risks in that it 
may make information presented about the BioTrust seem less important than the myriad other 
 147 
 
activities occurring in the post-partum period.  Salience refers to the importance of something 
(e.g. information about biobanking) relative to the surrounding environment (the postpartum 
unit) and competing demands for attention (e.g. the baby, the hospital staff, relatives and visitors, 
mothers’ post-partum emotional and physiological state) (Günther, Müller, & Geyer, 2016). It is 
possible that information about an optional decision without immediate consequences is simply 
not important given the environment. Yet, some ethicists consider biobanking more than minimal 
risk especially when it involves surrogate consent for minors (Baumann, 2001; Caulfield & 
Weijer, 2009; Hens, Cassiman, Nys, & Dierickx, 2011; Hofmann, 2009). Multiple leading 
maternal-child health organizations and researchers have called for moving education about NBS 
and the use of rDBS to the prenatal setting (American College of Obstetricians and 
Gynecologists, 2015; American Academy of Pediatrics, Newborn Screening Authoring 
Committee, 2008). In contrast to stakeholders’ concerns that education will lead to more refusals 
to participate, evidence shows that educational efforts actually increase support for NBS and 
rDBS research (Botkin et al., 2016).  In addition, the healthcare system and research enterprise 
should allow new parents to attend to the birth experience without having to make these 
decisions during the post-partum period. Other points in time, ideally early in the prenatal 
setting, would better allow time for discussion and further deliberation. 
 Fathers were important influence on mother’s decisions to donate their newborn’s blood 
spots for research. During the interviews, fathers were observed to ask or answer questions, even 
though research questions were intended for and directed to the mother. It was observed that 
decision-making about blood spot donation was often a joint decision between the parents of the 
newborn.  While fathers’ level of biobanking knowledge and involvement in this decision was 
not specifically assessed in this study, from interactions observed during the consent process it 
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appeared that they wanted to be engaged in the education and decision-making process. Further 
exploration is needed on the father’s decision-making relative to rDBS research and biobanking.  
Limitations and Strengths 
 There were three primary limitations to the empirical research in this dissertation. First, 
the qualitative and quantitative studies of this research had small samples of participants from 
only one state, which limits the generalizability of study findings.  While the qualitative sample 
of 20 mothers was a convenience sample from a single data collection site, data saturation was 
achieved, adding strength to its adequacy and validity (Guest, Bunce & Johnson, 2006; Polit & 
Hungler, 1999). Despite sending a reminder postcard one week after the initial survey mailing, 
and a $2 honorarium included in the mailing, the response rate for the survey was only 17% 
(N=80).  Larger incentives and repeated mailings were simply not financially feasible and 
therefore results should be interpreted with caution.  This small sample may represent a response 
bias and because the survey was anonymous, data on non-respondents was not able to be 
collected.  Surveys were mailed to mothers who gave birth within the last 3 months in order to 
minimize recall bias. However, as new mothers are often tired and stressed, this may have 
contributed to the low response rate.   
Second, the MMIC (Marteau et al., 2001) restricts the definition an informed choice to 
the categories of knowledge, attitudes, and participation decisions, and an informed choice may 
be more complex and involve a component of deliberation, not captured in the MMIC (van den 
Berg et al. 2006).  However, the novel application of MMIC to data on mothers’ decisions about 
donating their newborns’ blood spots for research was a strength of the study. Findings from the 
qualitative study indicated many mothers who agreed to donate had poor knowledge and were 
often unaware of their knowledge gaps and misinformation. Similar findings of poor knowledge 
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have been reported in individuals with diabetes making health related decisions in that 
individuals who lack knowledge of diabetes may fail to recognize the relevance of important 
health information, impacting health related decision-making (St. Jean, 2017).  In contrast, five 
of the six mothers who declined to donate did recognize the inadequacy of their own knowledge 
of biobanking and declined to participate.  Declining to participate in a study when one 
recognizes that he or she possess poor knowledge is viewed as a rational decision, but does not 
constitute an informed choice according to Marteau et al. (2001).  Increased knowledge and 
understanding may increase participation (Jallo et al., 2013; Quinn et al., 2012).  It has been 
suggested that individuals who agree to participate in clinical research or biobanking may need 
to demonstrate higher knowledge scores than decliners because they are exposing themselves (or 
their newborns) to additional risks (Roth, Meisel, & Lidz, 1977).  In addition, dichotomized 
categories may have overlooked gradations in the interview data.  This is perhaps especially true 
in the quantitative research, where dichotomizing continuous data is often considered 
controversial (Dawson & Weiss, 2012). Lastly, only one consenter at a single institution was 
observed in the qualitative interviews. Variations in organizational policies, level of training, and 
individual differences may exist at other institutions and in other consenters. Nevertheless, this 
does not negate the need for consistent training for all consenters and observing only one 
consenter provided a degree of consistency in the study.  
 There are several strengths to the study.  The qualitative interviews produced rich, 
detailed data and captured the mothers’ decision-making process as it occurred. The examination 
of actual, real-time decisions that occurred in their natural environment on the post-partum unit 
was a noted strength of the study, as was the ability to observe the effects of context on decision-
making.  Additional strengths included the use of standardized measures to assess biobanking 
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knowledge, attitudes, self-efficacy, intrinsic religiosity, and personal values. Standardized 
measures make comparisons across studies more feasible and have been under-utilized in studies 
on understanding informed consent for biobanking (Eisenhauer et al., 2017).  
Future Research   
 Findings from this study indicate that knowledge and experience contribute to making an 
informed choice about biobanking.  Introducing information and education about NBS and 
research use of rDBS, and perhaps even the consent request, in the prenatal environment would 
provide more exposure to biobanking information, allow parents time to deliberate, and may aid 
informed choices especially for first time parents (American College of Obstetricians and 
Gynecologists, 2015; American Academy of Pediatrics, 2008; Botkin et al., 2016; van den Berg 
et al., 2006).  Follow-up studies should be conducted to determine if this change improves 
understanding and ultimately the proportion of mothers making informed choices.  
 Additional research on the role of values in decision-making about biobanking is needed. 
The use of decision aids that include more balanced information and value clarification exercises 
may aid informed choice (Stacey et al., 2017).  Likewise, the role of nurses in explaining and 
obtaining consent need further study.  Nurses possess key communication skills to aid values-
clarification and hold ethical discussions, at the same time the public’s trust in nurses must not 
be exploited or misused.  Research on the basic competencies of informed consent and best 
practices for teaching these skills needs is urgently needed (Gaeta, Torres, Kotamraju, Seidman, 
& Yarmush, 2007; McClean & Card, 2004; Sherman, McGaghie, Unti, & Thomas, 2005). 
Necessary competencies for informed consent include communication skills, value-clarification 
techniques, and principles of shared decision-making. Methods of teaching these skills may 
include the use of case studies, simulation and role-playing, and educational videos (Gaeta et al., 
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2007; McClean & Card, 2004; Sherman, et al., 2005).  Once such competencies and best 
practices are determined, policies need to be implemented to require that these competencies are 
met by all consenters and skills maintained by annual training sessions across organizations and 
state lines to uphold the federal regulations on protecting human subjects.   
Conclusion 
  This dissertation research provides valuable insight into informed choices being made 
about biobanking participation, specifically in regard to biobanking newborn rDBS. Future work 
is needed to more fully understand the content, context, and delivery of education about NBS 
and research use of rDBS.  Practicability, administrative convenience, and efficacy of 
biospecimens accrual should not override ethics (Baumann, 2001).  Nurses need to advocate for 
biobanking decisions to be informed choices, based on adequate knowledge and in accordance 
with personal values, to uphold the true meaning and spirit of informed consent and to respect 
the dignity, worth, and moral agency of all individuals.  
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Appendix A 
Quality of evidence checklist for studies of informed consent:  
Adapted from:  Edwards, S. J., Lilford, R. J., Thornton, J., & Hewison, J. (1998). Informed 
consent for clinical trials: in search of the “best” method. Social Science & Medicine, 47(11), 
1825-1840 and Cohn, E., & Larson, E. (2007). Improving participant comprehension in the 
informed consent process. Journal of Nursing Scholarship, 39(3), 273-280. 
(A) sampling hierarchy: sampling (0) not stated or convenience; (1) all biobank participants 
offered entry in a study on understanding informed consent  or random sample of all biobanking 
participants. (B) outcome measurement: (0) reliability/validity not addressed; (1) 
reliability/validity addressed in study (some validity /reliability testing, content validity testing 
by experts, piloting, inter-rater reliability testing) but no statistical measures reported or available 
(i.e. no published reliability/validity data on the instrument); (2) use of a an instrument with 
published reliability and validity data (e.g. test–retest reliability intra-class correlation 
coefficients, Cronbach’s alpha, Q-Kappa). (C) response rate: response rate to outcome measure 
must be given and acceptable at 70% or above (0) not given or < 70% (1) ≥70% (D) actual 
information given at consent  (i.e. informed consent document)  and questionnaire (or interview 
guide) should be supplied in the study (including made available online as supplemental 
material) (0) not supplied (1) supplied *(E) study includes an author affiliated with a biobank or 
funding associated with biobanking: (0) yes/(1) no/unknown.   
Possible 6 points Total  
*This source of bias has been discussed in the work of Master et al., 2012 and Roessler et al. 2015. 
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Appendix B BANKS 
 
Biobanking Attitudes and Knowledge Survey (BANKS) 
Please circle your response  
 
Please note: The term “biospecimen” refers to substances taken from the human body, 
such as tissue, blood, plasma, and urine. For this survey, please think about 
biospecimens as the leftover dried bloodspots from your newborn’s screening tests. 
 
BANKS – Attitudes  
Response scale: Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly 
Disagree 
1. Giving a biospecimen is for the greater good of society 
Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
2. People who give biospecimens help prevent diseases 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
3. People who give biospecimens help cure diseases 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
4. Giving a biospecimen is a waste of a person’s time 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
5. Giving a  biospecimen will help future generations 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
 
 161 
 
6. Giving a  biospecimen gets in the way of a person’s medical care 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
7. Giving a biospecimen will help a person’s family 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
8. Medical information is unlikely to be stolen from a biobank 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
9. Giving blood to a biobank is a good way to help cancer research 
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
10. Personal information is unlikely to be stolen from a biobank  
 Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
11. A person’s family medical information is safe in a biobank  
Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
12. Biospecimens that people donate might be used for purposes they do not want 
Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
13. A person should not donate biospecimens because it may identify health problems 
Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
14. Giving biospecimens to a biobank may lead to more health care costs 
Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree 
BANKS – Knowledge  
Response scale: Yes, No, Don’t Know 
1. A person has to spend money to give a biospecimen  
Yes, No, Don’t Know 
2. Anyone can access the biospecimens people give  
Yes, No, Don’t Know 
3. Research results from biospecimens will show up in medical records  
Yes, No, Don’t Know 
4. Biospecimens given to a biobank will be sold to drug companies  
Yes, No, Don’t Know 
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5. A scientist must keep a person’s information private when doing research  
Yes, No, Don’t Know 
6. The biospecimens people give can be sent to any organization that requests them  
Yes, No, Don’t Know 
7. Police departments can legally get the biospecimens a person gives  
Yes, No, Don’t Know  
8. Biospecimens given to a biobank can be sold to anyone  
Yes, No, Don’t Know 
9. Insurance companies can legally get the biospecimens a person gives  
Yes, No, Don’t Know 
10. Researchers will always contact people if their biospecimens show risk for a disease  
Yes, No, Don’t Know 
11. A person’s family can get information about the biospecimens a person gives  
Yes, No, Don’t Know 
12. People can make money from donated biospecimens  
Yes, No, Don’t Know 
13. People no longer own their biospecimens after they give them to a biobank  
Yes, No, Don’t Know 
14. After a person gives a biospecimen to a biobank, she/he can get it back  
Yes, No, Don’t Know 
15. A person might be cloned if he/she donates a biospecimen to a biobank  
Yes, No, Don’t Know 
16. A person can stop being in a research study after giving a biospecimen 
Yes, No, Don’t Know 
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BANKS – Self-Efficacy  
Response scale: 0= cannot do to  . . . . . . . 10 = highly, certainly can do 
(0= Cannot do, 5= Moderately, Certain Can Do, 10= Highly, Certain Can Do).  
1. I think I could give a biospecimen to a biobank even if I have not donated a biospecimen 
before 
 
2. I think I could give a biospecimen to a biobank even if I had to travel far to do so 
 
3. I think I could give a biospecimen to a biobank even if it hurts 
 
4. I think I could give blood to a biobank even if I feel weak 
 
5. I think I could give a biospecimen to a biobank even if my family does not want me to 
 
6. I think I could give a biospecimen to a biobank even if it is against my cultural beliefs 
 
7. I think I could give blood to a biobank even if it hurts 
 
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
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8. I think I could give a biospecimen to a biobank even if I am worried about how it will be 
used 
 
9. I think I could give a biospecimen to a biobank even if I am not feeling well 
 
10. I think I could give a biospecimen to a biobank even if I am afraid of  needles 
 
11. I think I could give a biospecimen to a biobank even if it is against my religious beliefs 
 
12. I think I could give a biospecimen to a biobank even if I have to spend more time at a 
doctor’s office 
 
 
Source: Wells, K.J., Arevalo, M., Meade, C.D., Gwede, C.K., Quinn, G.P., Luque, J.S., San 
Miguel, G.,Watson, D., Phillips, R., Reyes, C., Romo, M., West, J., Jacobsen, P.B. (2014).  
Development and validation of the biobanking attitudes and knowledge survey (BANKS). 
Cancer Epidemiology, Biomarkers & Prevention, 23(3), 374-82. 
 
 
  
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
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Appendix C  Hoge intrinsic religiosity motivation scale 
Note: There is no agreement about right or wrong attitudes on these questions. 
1. My faith involves all of my life 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
2. In my life, I experience the presence of the Divine (i.e., God) 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
3. Although I am a religious person, I refuse to let religious considerations influence my 
everyday affairs  
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
4. Nothing is as important to me as serving God as best as I know how 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
5. My faith sometimes restricts my actions 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
6. My religious beliefs are what really lie behind my whole approach to life 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
7. I try hard to carry my religion over into all my other dealings in life 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
8. One should seek God's guidance when making every important decision 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
9. Although I believe in religion, I feel there are many more important things in life 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
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10. It does not matter so much what I believe as long as I lead a moral life 
1-strongly agree 2- agree 3-disagree 4-strongly disagree 
 
Source: Hoge, R. (1972). A validated intrinsic religious motivation scale. Journal for the 
Scientific Study of Religion, 11(4), 369–376. http://doi.org/10.2307/1384677.  
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Appendix D The Short Schwartz’s Value Survey 
Rate the importance of the following values as a life-guiding principle for you 
Use the following scale for rating each value using scale:  0 1 2 3 4 5 6 7 8 
in which: 0= opposed to my principles,  1= not important, 4= important, 8= of supreme 
importance. 
 
 
opposed 
to my 
principles 
not 
important 
 Important  of supreme 
importance 
1. POWER (social power, 
authority, wealth)                                                 
0 1 2 3 4 5 6 7 8 
2. ACHIEVEMENT (success, 
capability, ambition, influence 
on people and     events)                                                                                                   
0 1 2 3 4 5 6 7 8 
3. HEDONISM (gratification of 
desires, enjoyment in life, self-
indulgence)                 
0 1 2 3 4 5 6 7 8 
4. STIMULATION (daring, a 
varied and challenging life, an 
exciting life)                   
0 1 2 3 4 5 6 7 8 
5. SELF-DIRECTION 
(creativity, freedom, curiosity, 
independence, choosing     one's 
own goals)                                                                                       
0 1 2 3 4 5 6 7 8 
6. UNIVERSALISM (broad-
mindedness, beauty of nature 
and arts, social   justice, a world 
at peace, equality, wisdom, 
unity with nature,environmental 
protection)                      
0 1 2 3 4 5 6 7 8 
7. BENEVOLENCE 
(helpfulness, honesty, 
forgiveness, loyalty, 
responsibility)                
0 1 2 3 4 5 6 7 8 
8. TRADITION (respect for 
tradition, humbleness, accepting 
one's portion in   life, devotion, 
modesty)                                                                               
0 1 2 3 4 5 6 7 8 
9. CONFORMITY (obedience, 
honoring parents and elders, 
self-discipline,  politeness)                                                                                                 
0 1 2 3 4 5 6 7 8 
10. SECURITY (national 0 1 2 3 4 5 6 7 8 
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security, family security, social 
order, cleanliness,  reciprocation 
of favors)                                                                               
Source:Lindeman, M. & Verkasalo, M. (2005). Measuring values with the short Schwart’z 
value survey. Journal  of Personality Assessment, 85(2),170-178. 
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Appendix E Demographic Data 
1. Did you agree to give permission for this baby’s leftover blood spots to be used for 
research through the Michigan BioTrust? 
____Yes  
____No 
____I don’t remember 
2. Please indicate your race.  
____American Indian or Alaska Native 
____Asian 
____Black or African American  
____Hispanic or Latino 
____Native Hawaiian or Other Pacific Islander 
____White  
3. What is your current age? 
____18-25 
____26-45 
____46+ 
4. What is the highest level of education you completed? 
______4
th
-8
th
 grade______9
th
 -12
th
 grade 
_______Graduated from High School/GED 
_______Some College or vocational school 
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_______Associate’s Degree 
_______Bachelor’s Degree 
_______Master’s Degree  
 _______PhD or professional degree 
5. a) Do you identify with any specific religion?  
_____Yes ______No 
     b) If yes, what religion? 
6. (If yes to #5) Please circle the number on the line which is closest to your view. 
How important to you is the actual practice of your faith? 
 
#6. Adapted From King, M., Speck, P., & Thomas, A. (1995). The Royal Free interview for religious and spiritual beliefs: development and 
standardization. Psychological Medicine, 25(6), 1125-1134. 
7. What type of health insurance do you have?  
(For example: Blue Cross or Medicaid) 
____Public coverage (Medicaid) 
____Private coverage (Employer sponsored or directly purchased) 
8. a) How many live births have you had?    
  b) This is your ____ live birth. 
9. How many of your children were born in MI?  
10. In what years were they born in MI?   
11. Have you donated any other newborn’s leftover blood spots to a biobank? 
_____Yes _____  No _____  Unknown 
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Appendix F MDHHS Invitation Letter 
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Appendix H Eisenhauer Invitation 
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Appendix I Published article 
Reprinted with Permission 
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